JP2014518234A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2014518234A5 JP2014518234A5 JP2014517667A JP2014517667A JP2014518234A5 JP 2014518234 A5 JP2014518234 A5 JP 2014518234A5 JP 2014517667 A JP2014517667 A JP 2014517667A JP 2014517667 A JP2014517667 A JP 2014517667A JP 2014518234 A5 JP2014518234 A5 JP 2014518234A5
- Authority
- JP
- Japan
- Prior art keywords
- methyl
- triazolo
- quinoxaline
- chlorophenyl
- quinoxalin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 33
- QCQCHGYLTSGIGX-GHXANHINSA-N 4-[[(3ar,5ar,5br,7ar,9s,11ar,11br,13as)-5a,5b,8,8,11a-pentamethyl-3a-[(5-methylpyridine-3-carbonyl)amino]-2-oxo-1-propan-2-yl-4,5,6,7,7a,9,10,11,11b,12,13,13a-dodecahydro-3h-cyclopenta[a]chrysen-9-yl]oxy]-2,2-dimethyl-4-oxobutanoic acid Chemical compound N([C@@]12CC[C@@]3(C)[C@]4(C)CC[C@H]5C(C)(C)[C@@H](OC(=O)CC(C)(C)C(O)=O)CC[C@]5(C)[C@H]4CC[C@@H]3C1=C(C(C2)=O)C(C)C)C(=O)C1=CN=CC(C)=C1 QCQCHGYLTSGIGX-GHXANHINSA-N 0.000 description 12
- -1 pyridin-4-yloxy Chemical group 0.000 description 5
- 125000003349 3-pyridyl group Chemical group N1=C([H])C([*])=C([H])C([H])=C1[H] 0.000 description 3
- 125000004182 2-chlorophenyl group Chemical group [H]C1=C([H])C(Cl)=C(*)C([H])=C1[H] 0.000 description 2
- RBQZSOSIDAYTQQ-UHFFFAOYSA-N 4-[[1-[5-(2-methoxyethyl)pyridin-3-yl]-4-methyl-[1,2,4]triazolo[4,3-a]quinoxalin-8-yl]methyl]morpholine Chemical compound COCCC1=CN=CC(C=2N3C4=CC(CN5CCOCC5)=CC=C4N=C(C)C3=NN=2)=C1 RBQZSOSIDAYTQQ-UHFFFAOYSA-N 0.000 description 2
- 150000001412 amines Chemical class 0.000 description 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 2
- XSCHRSMBECNVNS-UHFFFAOYSA-N quinoxaline Chemical compound N1=CC=NC2=CC=CC=C21 XSCHRSMBECNVNS-UHFFFAOYSA-N 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- RFZHZDSZQMLWPM-UHFFFAOYSA-N (4-methyl-1-phenyl-[1,2,4]triazolo[4,3-a]quinoxalin-8-yl)methanol Chemical compound N=1N=C2C(C)=NC3=CC=C(CO)C=C3N2C=1C1=CC=CC=C1 RFZHZDSZQMLWPM-UHFFFAOYSA-N 0.000 description 1
- PBXNICUZJRRAJG-UHFFFAOYSA-N 1-(2,4-dichlorophenyl)-4-methyl-n-(pyridin-2-ylmethyl)-[1,2,4]triazolo[4,3-a]quinoxaline-8-carboxamide Chemical compound N=1N=C2C(C)=NC3=CC=C(C(=O)NCC=4N=CC=CC=4)C=C3N2C=1C1=CC=C(Cl)C=C1Cl PBXNICUZJRRAJG-UHFFFAOYSA-N 0.000 description 1
- UFSFBTVVLZCSCY-UHFFFAOYSA-N 1-(2,5-dichlorophenyl)-4-methyl-n-(pyridin-2-ylmethyl)-[1,2,4]triazolo[4,3-a]quinoxaline-8-carboxamide Chemical compound N=1N=C2C(C)=NC3=CC=C(C(=O)NCC=4N=CC=CC=4)C=C3N2C=1C1=CC(Cl)=CC=C1Cl UFSFBTVVLZCSCY-UHFFFAOYSA-N 0.000 description 1
- URLXPSUXGAGTAF-UHFFFAOYSA-N 1-(2,6-dichlorophenyl)-n-ethyl-4-methyl-[1,2,4]triazolo[4,3-a]quinoxaline-8-carboxamide Chemical compound N12C3=CC(C(=O)NCC)=CC=C3N=C(C)C2=NN=C1C1=C(Cl)C=CC=C1Cl URLXPSUXGAGTAF-UHFFFAOYSA-N 0.000 description 1
- DOKQEIRHEFIUMS-UHFFFAOYSA-N 1-(2-chloro-4-methoxyphenyl)-4-methyl-n-(pyridin-2-ylmethyl)-[1,2,4]triazolo[4,3-a]quinoxaline-8-carboxamide Chemical compound ClC1=CC(OC)=CC=C1C1=NN=C2N1C1=CC(C(=O)NCC=3N=CC=CC=3)=CC=C1N=C2C DOKQEIRHEFIUMS-UHFFFAOYSA-N 0.000 description 1
- ADXGWVHEMCWLBI-UHFFFAOYSA-N 1-(2-chloro-5-ethoxyphenyl)-4-methyl-8-(2-pyridin-3-ylethoxy)-[1,2,4]triazolo[4,3-a]quinoxaline Chemical compound CCOC1=CC=C(Cl)C(C=2N3C4=CC(OCCC=5C=NC=CC=5)=CC=C4N=C(C)C3=NN=2)=C1 ADXGWVHEMCWLBI-UHFFFAOYSA-N 0.000 description 1
- RHGSISTUFNGCAI-UHFFFAOYSA-N 1-(2-chloro-5-ethoxyphenyl)-4-methyl-8-(4-methylpiperazin-1-yl)-[1,2,4]triazolo[4,3-a]quinoxaline Chemical compound CCOC1=CC=C(Cl)C(C=2N3C4=CC(=CC=C4N=C(C)C3=NN=2)N2CCN(C)CC2)=C1 RHGSISTUFNGCAI-UHFFFAOYSA-N 0.000 description 1
- QPXNLQLXPDJMAK-UHFFFAOYSA-N 1-(2-chloro-5-ethoxyphenyl)-4-methyl-8-[(4-methylpiperazin-1-yl)methyl]-[1,2,4]triazolo[4,3-a]quinoxaline Chemical compound CCOC1=CC=C(Cl)C(C=2N3C4=CC(CN5CCN(C)CC5)=CC=C4N=C(C)C3=NN=2)=C1 QPXNLQLXPDJMAK-UHFFFAOYSA-N 0.000 description 1
- ICFQVFGTONAAIZ-UHFFFAOYSA-N 1-(2-chloro-5-ethoxyphenyl)-8-[(4-fluoropiperidin-1-yl)methyl]-4-methyl-[1,2,4]triazolo[4,3-a]quinoxaline Chemical compound CCOC1=CC=C(Cl)C(C=2N3C4=CC(CN5CCC(F)CC5)=CC=C4N=C(C)C3=NN=2)=C1 ICFQVFGTONAAIZ-UHFFFAOYSA-N 0.000 description 1
- RXSACHXZPRTNLY-UHFFFAOYSA-N 1-(2-chloro-5-fluorophenyl)-4-methyl-n-(pyridin-2-ylmethyl)-[1,2,4]triazolo[4,3-a]quinoxaline-8-carboxamide Chemical compound N=1N=C2C(C)=NC3=CC=C(C(=O)NCC=4N=CC=CC=4)C=C3N2C=1C1=CC(F)=CC=C1Cl RXSACHXZPRTNLY-UHFFFAOYSA-N 0.000 description 1
- KSVZPHFVGCYJBQ-UHFFFAOYSA-N 1-(2-chloro-5-methoxyphenyl)-4-methyl-n-(pyridin-2-ylmethyl)-[1,2,4]triazolo[4,3-a]quinoxaline-8-carboxamide Chemical compound COC1=CC=C(Cl)C(C=2N3C4=CC(=CC=C4N=C(C)C3=NN=2)C(=O)NCC=2N=CC=CC=2)=C1 KSVZPHFVGCYJBQ-UHFFFAOYSA-N 0.000 description 1
- RFPHPZFQKKOGCW-UHFFFAOYSA-N 1-(2-chloro-5-methoxyphenyl)-8-[(4-fluoropiperidin-1-yl)methyl]-4-methyl-[1,2,4]triazolo[4,3-a]quinoxaline Chemical compound COC1=CC=C(Cl)C(C=2N3C4=CC(CN5CCC(F)CC5)=CC=C4N=C(C)C3=NN=2)=C1 RFPHPZFQKKOGCW-UHFFFAOYSA-N 0.000 description 1
- IZFCCDRZSRDTDB-UHFFFAOYSA-N 1-(2-chloro-5-methylphenyl)-4-methyl-n-(pyridin-2-ylmethyl)-[1,2,4]triazolo[4,3-a]quinoxaline-8-carboxamide Chemical compound CC1=CC=C(Cl)C(C=2N3C4=CC(=CC=C4N=C(C)C3=NN=2)C(=O)NCC=2N=CC=CC=2)=C1 IZFCCDRZSRDTDB-UHFFFAOYSA-N 0.000 description 1
- DXMWTQIHTKNDCL-UHFFFAOYSA-N 1-(2-chloro-5-propan-2-yloxyphenyl)-4-methyl-8-(4-methylpiperazin-1-yl)-[1,2,4]triazolo[4,3-a]quinoxaline Chemical compound CC(C)OC1=CC=C(Cl)C(C=2N3C4=CC(=CC=C4N=C(C)C3=NN=2)N2CCN(C)CC2)=C1 DXMWTQIHTKNDCL-UHFFFAOYSA-N 0.000 description 1
- DXRORSSYLRSSCH-UHFFFAOYSA-N 1-(2-chloro-5-propan-2-yloxyphenyl)-4-methyl-8-[(4-methylpiperazin-1-yl)methyl]-[1,2,4]triazolo[4,3-a]quinoxaline Chemical compound CC(C)OC1=CC=C(Cl)C(C=2N3C4=CC(CN5CCN(C)CC5)=CC=C4N=C(C)C3=NN=2)=C1 DXRORSSYLRSSCH-UHFFFAOYSA-N 0.000 description 1
- SQCWLPYHEITKLZ-UHFFFAOYSA-N 1-(2-chloro-5-propan-2-yloxyphenyl)-8-[(4-fluoropiperidin-1-yl)methyl]-4-methyl-[1,2,4]triazolo[4,3-a]quinoxaline Chemical compound CC(C)OC1=CC=C(Cl)C(C=2N3C4=CC(CN5CCC(F)CC5)=CC=C4N=C(C)C3=NN=2)=C1 SQCWLPYHEITKLZ-UHFFFAOYSA-N 0.000 description 1
- KSLZFRSYFBPHNT-UHFFFAOYSA-N 1-(2-chloro-5-propoxyphenyl)-4-methyl-8-(2-pyridin-3-ylethoxy)-[1,2,4]triazolo[4,3-a]quinoxaline Chemical compound CCCOC1=CC=C(Cl)C(C=2N3C4=CC(OCCC=5C=NC=CC=5)=CC=C4N=C(C)C3=NN=2)=C1 KSLZFRSYFBPHNT-UHFFFAOYSA-N 0.000 description 1
- AJLATRGQTGOZDX-UHFFFAOYSA-N 1-(2-chloro-5-propoxyphenyl)-4-methyl-8-(4-methylpiperazin-1-yl)-[1,2,4]triazolo[4,3-a]quinoxaline Chemical compound CCCOC1=CC=C(Cl)C(C=2N3C4=CC(=CC=C4N=C(C)C3=NN=2)N2CCN(C)CC2)=C1 AJLATRGQTGOZDX-UHFFFAOYSA-N 0.000 description 1
- MWJHRMBPKCJYLL-UHFFFAOYSA-N 1-(2-chloro-5-propoxyphenyl)-4-methyl-8-[(4-methylpiperazin-1-yl)methyl]-[1,2,4]triazolo[4,3-a]quinoxaline Chemical compound CCCOC1=CC=C(Cl)C(C=2N3C4=CC(CN5CCN(C)CC5)=CC=C4N=C(C)C3=NN=2)=C1 MWJHRMBPKCJYLL-UHFFFAOYSA-N 0.000 description 1
- ROZSPBVQXAQIAI-INIZCTEOSA-N 1-(2-chloro-5-propoxyphenyl)-4-methyl-8-[[(2s)-pyrrolidin-2-yl]methoxy]-[1,2,4]triazolo[4,3-a]quinoxaline Chemical compound CCCOC1=CC=C(Cl)C(C=2N3C4=CC(OC[C@H]5NCCC5)=CC=C4N=C(C)C3=NN=2)=C1 ROZSPBVQXAQIAI-INIZCTEOSA-N 0.000 description 1
- YRVJDPUKLYCAAV-UHFFFAOYSA-N 1-(2-chloro-5-propoxyphenyl)-8-[(4-fluoropiperidin-1-yl)methyl]-4-methyl-[1,2,4]triazolo[4,3-a]quinoxaline Chemical compound CCCOC1=CC=C(Cl)C(C=2N3C4=CC(CN5CCC(F)CC5)=CC=C4N=C(C)C3=NN=2)=C1 YRVJDPUKLYCAAV-UHFFFAOYSA-N 0.000 description 1
- ADCUCKZPYWAEBQ-UHFFFAOYSA-N 1-(2-chloro-6-fluorophenyl)-8-ethenyl-4-methyl-[1,2,4]triazolo[4,3-a]quinoxaline Chemical compound N=1N=C2C(C)=NC3=CC=C(C=C)C=C3N2C=1C1=C(F)C=CC=C1Cl ADCUCKZPYWAEBQ-UHFFFAOYSA-N 0.000 description 1
- FDJDXMSUDXBHSQ-UHFFFAOYSA-N 1-(2-chlorophenyl)-4-methyl-7-(2-pyridin-2-ylethoxy)-[1,2,4]triazolo[4,3-a]quinoxaline Chemical compound C=1C=C2N3C(C=4C(=CC=CC=4)Cl)=NN=C3C(C)=NC2=CC=1OCCC1=CC=CC=N1 FDJDXMSUDXBHSQ-UHFFFAOYSA-N 0.000 description 1
- ZLNBADYTIGPAFU-UHFFFAOYSA-N 1-(2-chlorophenyl)-4-methyl-7-(trifluoromethoxy)-[1,2,4]triazolo[4,3-a]quinoxaline Chemical compound N=1N=C2C(C)=NC3=CC(OC(F)(F)F)=CC=C3N2C=1C1=CC=CC=C1Cl ZLNBADYTIGPAFU-UHFFFAOYSA-N 0.000 description 1
- RSAPMUKAYVUXCU-UHFFFAOYSA-N 1-(2-chlorophenyl)-4-methyl-8-(2-pyridin-2-ylethoxy)-[1,2,4]triazolo[4,3-a]quinoxaline Chemical compound C1=C2N3C(C=4C(=CC=CC=4)Cl)=NN=C3C(C)=NC2=CC=C1OCCC1=CC=CC=N1 RSAPMUKAYVUXCU-UHFFFAOYSA-N 0.000 description 1
- PNYVWIGFSKFFAW-UHFFFAOYSA-N 1-(2-chlorophenyl)-4-methyl-8-(4-methylpiperazin-1-yl)-[1,2,4]triazolo[4,3-a]quinoxaline Chemical compound C1CN(C)CCN1C1=CC=C(N=C(C)C=2N3C(C=4C(=CC=CC=4)Cl)=NN=2)C3=C1 PNYVWIGFSKFFAW-UHFFFAOYSA-N 0.000 description 1
- MMWSLKUAHUNFRG-UHFFFAOYSA-N 1-(2-chlorophenyl)-4-methyl-8-(trifluoromethoxy)-[1,2,4]triazolo[4,3-a]quinoxaline Chemical compound N=1N=C2C(C)=NC3=CC=C(OC(F)(F)F)C=C3N2C=1C1=CC=CC=C1Cl MMWSLKUAHUNFRG-UHFFFAOYSA-N 0.000 description 1
- QINZPNYWORORJH-UHFFFAOYSA-N 1-(2-chlorophenyl)-4-methyl-8-[(4-methylpiperazin-1-yl)methyl]-[1,2,4]triazolo[4,3-a]quinoxaline Chemical compound C1CN(C)CCN1CC1=CC=C(N=C(C)C=2N3C(C=4C(=CC=CC=4)Cl)=NN=2)C3=C1 QINZPNYWORORJH-UHFFFAOYSA-N 0.000 description 1
- RNDRKGWDIXCGGN-UHFFFAOYSA-N 1-(2-chlorophenyl)-4-methyl-[1,2,4]triazolo[4,3-a]quinoxalin-8-amine Chemical compound N=1N=C2C(C)=NC3=CC=C(N)C=C3N2C=1C1=CC=CC=C1Cl RNDRKGWDIXCGGN-UHFFFAOYSA-N 0.000 description 1
- UQIZGVMJUBAZMQ-UHFFFAOYSA-N 1-(2-chlorophenyl)-4-methyl-[1,2,4]triazolo[4,3-a]quinoxalin-8-ol Chemical compound N=1N=C2C(C)=NC3=CC=C(O)C=C3N2C=1C1=CC=CC=C1Cl UQIZGVMJUBAZMQ-UHFFFAOYSA-N 0.000 description 1
- CTBSIWZADWNGPL-UHFFFAOYSA-N 1-(2-chlorophenyl)-4-methyl-[1,2,4]triazolo[4,3-a]quinoxaline Chemical compound N=1N=C2C(C)=NC3=CC=CC=C3N2C=1C1=CC=CC=C1Cl CTBSIWZADWNGPL-UHFFFAOYSA-N 0.000 description 1
- BNSTYXVEOJNFJM-UHFFFAOYSA-N 1-(2-chlorophenyl)-4-methyl-[1,2,4]triazolo[4,3-a]quinoxaline-8-carboxylic acid Chemical compound N=1N=C2C(C)=NC3=CC=C(C(O)=O)C=C3N2C=1C1=CC=CC=C1Cl BNSTYXVEOJNFJM-UHFFFAOYSA-N 0.000 description 1
- OKUUWEOFPDWWAJ-UHFFFAOYSA-N 1-(2-chlorophenyl)-4-methyl-n-(1-methylpiperidin-4-yl)-[1,2,4]triazolo[4,3-a]quinoxalin-8-amine Chemical compound C1CN(C)CCC1NC1=CC=C(N=C(C)C=2N3C(C=4C(=CC=CC=4)Cl)=NN=2)C3=C1 OKUUWEOFPDWWAJ-UHFFFAOYSA-N 0.000 description 1
- FGXIRQDNKXCFIL-UHFFFAOYSA-N 1-(2-chlorophenyl)-4-methyl-n-(1-methylpiperidin-4-yl)-[1,2,4]triazolo[4,3-a]quinoxaline-8-carboxamide Chemical compound C1CN(C)CCC1NC(=O)C1=CC=C(N=C(C)C=2N3C(C=4C(=CC=CC=4)Cl)=NN=2)C3=C1 FGXIRQDNKXCFIL-UHFFFAOYSA-N 0.000 description 1
- LEZMGPUUKQUXJN-UHFFFAOYSA-N 1-(2-chlorophenyl)-4-methyl-n-(2-morpholin-4-ylethyl)-[1,2,4]triazolo[4,3-a]quinoxalin-8-amine Chemical compound C1=C2N3C(C=4C(=CC=CC=4)Cl)=NN=C3C(C)=NC2=CC=C1NCCN1CCOCC1 LEZMGPUUKQUXJN-UHFFFAOYSA-N 0.000 description 1
- IFWAHVQKYGJWGP-UHFFFAOYSA-N 1-(2-chlorophenyl)-4-methyl-n-(2-morpholin-4-ylethyl)-[1,2,4]triazolo[4,3-a]quinoxaline-8-carboxamide Chemical compound N=1N=C2C(C)=NC3=CC=C(C(=O)NCCN4CCOCC4)C=C3N2C=1C1=CC=CC=C1Cl IFWAHVQKYGJWGP-UHFFFAOYSA-N 0.000 description 1
- XNYYCWIPILCSBL-UHFFFAOYSA-N 1-(2-chlorophenyl)-4-methyl-n-(2-phenylethyl)-[1,2,4]triazolo[4,3-a]quinoxaline-8-carboxamide Chemical compound N=1N=C2C(C)=NC3=CC=C(C(=O)NCCC=4C=CC=CC=4)C=C3N2C=1C1=CC=CC=C1Cl XNYYCWIPILCSBL-UHFFFAOYSA-N 0.000 description 1
- RHFWGIGDAGTINL-UHFFFAOYSA-N 1-(2-chlorophenyl)-4-methyl-n-(2-piperidin-1-ylethyl)-[1,2,4]triazolo[4,3-a]quinoxaline-8-carboxamide Chemical compound N=1N=C2C(C)=NC3=CC=C(C(=O)NCCN4CCCCC4)C=C3N2C=1C1=CC=CC=C1Cl RHFWGIGDAGTINL-UHFFFAOYSA-N 0.000 description 1
- YUYKNZMIAJIBOA-UHFFFAOYSA-N 1-(2-chlorophenyl)-4-methyl-n-(2-pyridin-2-ylethyl)-[1,2,4]triazolo[4,3-a]quinoxalin-8-amine Chemical compound C1=C2N3C(C=4C(=CC=CC=4)Cl)=NN=C3C(C)=NC2=CC=C1NCCC1=CC=CC=N1 YUYKNZMIAJIBOA-UHFFFAOYSA-N 0.000 description 1
- KTVOIZSPBSYWIC-UHFFFAOYSA-N 1-(2-chlorophenyl)-4-methyl-n-(2-pyrrolidin-1-ylethyl)-[1,2,4]triazolo[4,3-a]quinoxaline-8-carboxamide Chemical compound N=1N=C2C(C)=NC3=CC=C(C(=O)NCCN4CCCC4)C=C3N2C=1C1=CC=CC=C1Cl KTVOIZSPBSYWIC-UHFFFAOYSA-N 0.000 description 1
- MGKVGJJPEDPCEQ-UHFFFAOYSA-N 1-(2-chlorophenyl)-4-methyl-n-(3,4,5-trimethoxyphenyl)-[1,2,4]triazolo[4,3-a]quinoxaline-8-carboxamide Chemical compound COC1=C(OC)C(OC)=CC(NC(=O)C=2C=C3N4C(C=5C(=CC=CC=5)Cl)=NN=C4C(C)=NC3=CC=2)=C1 MGKVGJJPEDPCEQ-UHFFFAOYSA-N 0.000 description 1
- AWMOIFLKHCCNSA-UHFFFAOYSA-N 1-(2-chlorophenyl)-4-methyl-n-(pyridin-2-ylmethyl)-[1,2,4]triazolo[4,3-a]quinoxaline-8-carboxamide Chemical compound N=1N=C2C(C)=NC3=CC=C(C(=O)NCC=4N=CC=CC=4)C=C3N2C=1C1=CC=CC=C1Cl AWMOIFLKHCCNSA-UHFFFAOYSA-N 0.000 description 1
- VYUJHYUPDPKIJI-UHFFFAOYSA-N 1-(2-chlorophenyl)-8-(1,1-difluoroethoxy)-4-methyl-[1,2,4]triazolo[4,3-a]quinoxaline Chemical compound N=1N=C2C(C)=NC3=CC=C(OC(C)(F)F)C=C3N2C=1C1=CC=CC=C1Cl VYUJHYUPDPKIJI-UHFFFAOYSA-N 0.000 description 1
- KYFKQTJBDJLLCX-UHFFFAOYSA-N 1-(2-chlorophenyl)-8-[(3-methoxypiperidin-1-yl)methyl]-4-methyl-[1,2,4]triazolo[4,3-a]quinoxaline Chemical compound C1C(OC)CCCN1CC1=CC=C(N=C(C)C=2N3C(C=4C(=CC=CC=4)Cl)=NN=2)C3=C1 KYFKQTJBDJLLCX-UHFFFAOYSA-N 0.000 description 1
- CPSWTJWDYWGXCK-UHFFFAOYSA-N 1-(2-chlorophenyl)-8-[(4-fluoropiperidin-1-yl)methyl]-4-methyl-[1,2,4]triazolo[4,3-a]quinoxaline Chemical compound C1=C2N3C(C=4C(=CC=CC=4)Cl)=NN=C3C(C)=NC2=CC=C1CN1CCC(F)CC1 CPSWTJWDYWGXCK-UHFFFAOYSA-N 0.000 description 1
- UZSLMTQHJNJZLV-UHFFFAOYSA-N 1-(2-chlorophenyl)-8-[(4-methoxypiperidin-1-yl)methyl]-4-methyl-[1,2,4]triazolo[4,3-a]quinoxaline Chemical compound C1CC(OC)CCN1CC1=CC=C(N=C(C)C=2N3C(C=4C(=CC=CC=4)Cl)=NN=2)C3=C1 UZSLMTQHJNJZLV-UHFFFAOYSA-N 0.000 description 1
- KHYIRYRWPBUBTC-UHFFFAOYSA-N 1-(2-chlorophenyl)-8-[[3-(methoxymethyl)pyrrolidin-1-yl]methyl]-4-methyl-[1,2,4]triazolo[4,3-a]quinoxaline Chemical compound C1C(COC)CCN1CC1=CC=C(N=C(C)C=2N3C(C=4C(=CC=CC=4)Cl)=NN=2)C3=C1 KHYIRYRWPBUBTC-UHFFFAOYSA-N 0.000 description 1
- WMIGIQZRGONALR-UHFFFAOYSA-N 1-(2-chlorophenyl)-8-ethenyl-4-methyl-[1,2,4]triazolo[4,3-a]quinoxaline Chemical compound N=1N=C2C(C)=NC3=CC=C(C=C)C=C3N2C=1C1=CC=CC=C1Cl WMIGIQZRGONALR-UHFFFAOYSA-N 0.000 description 1
- IQFAUAIVCNIZMA-UHFFFAOYSA-N 1-(2-chlorophenyl)-8-methoxy-4-methyl-[1,2,4]triazolo[4,3-a]quinoxaline Chemical compound N12C3=CC(OC)=CC=C3N=C(C)C2=NN=C1C1=CC=CC=C1Cl IQFAUAIVCNIZMA-UHFFFAOYSA-N 0.000 description 1
- GUTVZXOGCBCORY-UHFFFAOYSA-N 1-(2-chlorophenyl)-n,4-dimethyl-[1,2,4]triazolo[4,3-a]quinoxaline-8-carboxamide Chemical compound N12C3=CC(C(=O)NC)=CC=C3N=C(C)C2=NN=C1C1=CC=CC=C1Cl GUTVZXOGCBCORY-UHFFFAOYSA-N 0.000 description 1
- VWVKVFZRFDUMRX-UHFFFAOYSA-N 1-(2-chlorophenyl)-n,n,4-trimethyl-[1,2,4]triazolo[4,3-a]quinoxalin-8-amine Chemical compound N12C3=CC(N(C)C)=CC=C3N=C(C)C2=NN=C1C1=CC=CC=C1Cl VWVKVFZRFDUMRX-UHFFFAOYSA-N 0.000 description 1
- PKTLZXQQPTWMHC-UHFFFAOYSA-N 1-(2-chlorophenyl)-n-(2-fluoroethyl)-4-methyl-[1,2,4]triazolo[4,3-a]quinoxaline-8-carboxamide Chemical compound N=1N=C2C(C)=NC3=CC=C(C(=O)NCCF)C=C3N2C=1C1=CC=CC=C1Cl PKTLZXQQPTWMHC-UHFFFAOYSA-N 0.000 description 1
- OVXRFSFTWQJRAZ-UHFFFAOYSA-N 1-(2-chlorophenyl)-n-(2-hydroxyethyl)-4-methyl-[1,2,4]triazolo[4,3-a]quinoxaline-8-carboxamide Chemical compound N=1N=C2C(C)=NC3=CC=C(C(=O)NCCO)C=C3N2C=1C1=CC=CC=C1Cl OVXRFSFTWQJRAZ-UHFFFAOYSA-N 0.000 description 1
- OJADSQAKVCVDIT-UHFFFAOYSA-N 1-(2-chlorophenyl)-n-(2-methoxyethyl)-4-methyl-[1,2,4]triazolo[4,3-a]quinoxalin-8-amine Chemical compound N12C3=CC(NCCOC)=CC=C3N=C(C)C2=NN=C1C1=CC=CC=C1Cl OJADSQAKVCVDIT-UHFFFAOYSA-N 0.000 description 1
- YJFZEKFUCDMNNG-UHFFFAOYSA-N 1-(2-chlorophenyl)-n-(2-methoxyethyl)-4-methyl-[1,2,4]triazolo[4,3-a]quinoxaline-8-carboxamide Chemical compound N12C3=CC(C(=O)NCCOC)=CC=C3N=C(C)C2=NN=C1C1=CC=CC=C1Cl YJFZEKFUCDMNNG-UHFFFAOYSA-N 0.000 description 1
- IIJNPKDFXOKUPY-UHFFFAOYSA-N 1-(2-chlorophenyl)-n-[(4-fluoropyridin-2-yl)methyl]-4-methyl-[1,2,4]triazolo[4,3-a]quinoxaline-8-carboxamide Chemical compound N=1N=C2C(C)=NC3=CC=C(C(=O)NCC=4N=CC=C(F)C=4)C=C3N2C=1C1=CC=CC=C1Cl IIJNPKDFXOKUPY-UHFFFAOYSA-N 0.000 description 1
- WUDYWLZBZXXXMD-UHFFFAOYSA-N 1-(2-chlorophenyl)-n-[(6-fluoropyridin-2-yl)methyl]-4-methyl-[1,2,4]triazolo[4,3-a]quinoxaline-8-carboxamide Chemical compound N=1N=C2C(C)=NC3=CC=C(C(=O)NCC=4N=C(F)C=CC=4)C=C3N2C=1C1=CC=CC=C1Cl WUDYWLZBZXXXMD-UHFFFAOYSA-N 0.000 description 1
- SRITYIMQTYHWHI-UHFFFAOYSA-N 1-(2-chlorophenyl)-n-[2-(diethylamino)ethyl]-4-methyl-[1,2,4]triazolo[4,3-a]quinoxaline-8-carboxamide Chemical compound N12C3=CC(C(=O)NCCN(CC)CC)=CC=C3N=C(C)C2=NN=C1C1=CC=CC=C1Cl SRITYIMQTYHWHI-UHFFFAOYSA-N 0.000 description 1
- JHNQIJOFPJQWJX-UHFFFAOYSA-N 1-(2-chlorophenyl)-n-ethyl-4-methyl-[1,2,4]triazolo[4,3-a]quinoxaline-8-carboxamide Chemical compound N12C3=CC(C(=O)NCC)=CC=C3N=C(C)C2=NN=C1C1=CC=CC=C1Cl JHNQIJOFPJQWJX-UHFFFAOYSA-N 0.000 description 1
- JWUTVUKQJDFDSE-UHFFFAOYSA-N 1-(2-methoxyphenyl)-4-methyl-n-(pyridin-2-ylmethyl)-[1,2,4]triazolo[4,3-a]quinoxaline-8-carboxamide Chemical compound COC1=CC=CC=C1C1=NN=C2N1C1=CC(C(=O)NCC=3N=CC=CC=3)=CC=C1N=C2C JWUTVUKQJDFDSE-UHFFFAOYSA-N 0.000 description 1
- RMKCJJPZQJQEJH-UHFFFAOYSA-N 1-(5-butoxy-2-chlorophenyl)-4-methyl-8-(2-pyridin-3-ylethoxy)-[1,2,4]triazolo[4,3-a]quinoxaline Chemical compound CCCCOC1=CC=C(Cl)C(C=2N3C4=CC(OCCC=5C=NC=CC=5)=CC=C4N=C(C)C3=NN=2)=C1 RMKCJJPZQJQEJH-UHFFFAOYSA-N 0.000 description 1
- MMQGTSRDDFFUBC-UHFFFAOYSA-N 1-(5-butoxy-2-chlorophenyl)-4-methyl-8-(4-methylpiperazin-1-yl)-[1,2,4]triazolo[4,3-a]quinoxaline Chemical compound CCCCOC1=CC=C(Cl)C(C=2N3C4=CC(=CC=C4N=C(C)C3=NN=2)N2CCN(C)CC2)=C1 MMQGTSRDDFFUBC-UHFFFAOYSA-N 0.000 description 1
- HWEOCPNBTWYYMW-UHFFFAOYSA-N 1-(5-butoxy-2-chlorophenyl)-4-methyl-8-(pyrrolidin-1-ylmethyl)-[1,2,4]triazolo[4,3-a]quinoxaline Chemical compound CCCCOC1=CC=C(Cl)C(C=2N3C4=CC(CN5CCCC5)=CC=C4N=C(C)C3=NN=2)=C1 HWEOCPNBTWYYMW-UHFFFAOYSA-N 0.000 description 1
- PXXAALYWDIZMGZ-UHFFFAOYSA-N 1-(5-butoxy-2-chlorophenyl)-4-methyl-8-[(4-methylpiperazin-1-yl)methyl]-[1,2,4]triazolo[4,3-a]quinoxaline Chemical compound CCCCOC1=CC=C(Cl)C(C=2N3C4=CC(CN5CCN(C)CC5)=CC=C4N=C(C)C3=NN=2)=C1 PXXAALYWDIZMGZ-UHFFFAOYSA-N 0.000 description 1
- JMYZWLOOMRTTEP-UHFFFAOYSA-N 1-(5-butoxy-2-chlorophenyl)-8-[(4-fluoropiperidin-1-yl)methyl]-4-methyl-[1,2,4]triazolo[4,3-a]quinoxaline Chemical compound CCCCOC1=CC=C(Cl)C(C=2N3C4=CC(CN5CCC(F)CC5)=CC=C4N=C(C)C3=NN=2)=C1 JMYZWLOOMRTTEP-UHFFFAOYSA-N 0.000 description 1
- PFISWSGRVIUKTH-UHFFFAOYSA-N 1-(5-butoxy-2-fluorophenyl)-4-methyl-[1,2,4]triazolo[4,3-a]quinoxaline-7-carbonitrile Chemical compound CCCCOC1=CC=C(F)C(C=2N3C4=CC=C(C=C4N=C(C)C3=NN=2)C#N)=C1 PFISWSGRVIUKTH-UHFFFAOYSA-N 0.000 description 1
- KIEDFQWRZWIXHW-UHFFFAOYSA-N 1-(5-butoxy-2-fluorophenyl)-4-methyl-[1,2,4]triazolo[4,3-a]quinoxaline-8-carbonitrile Chemical compound CCCCOC1=CC=C(F)C(C=2N3C4=CC(=CC=C4N=C(C)C3=NN=2)C#N)=C1 KIEDFQWRZWIXHW-UHFFFAOYSA-N 0.000 description 1
- CZPHYYDBRSZQLO-UHFFFAOYSA-N 1-(5-butoxypyridin-3-yl)-4-methyl-8-(pyrrolidin-1-ylmethyl)-[1,2,4]triazolo[4,3-a]quinoxaline Chemical compound CCCCOC1=CN=CC(C=2N3C4=CC(CN5CCCC5)=CC=C4N=C(C)C3=NN=2)=C1 CZPHYYDBRSZQLO-UHFFFAOYSA-N 0.000 description 1
- ATLVGHFNDQLLKU-UHFFFAOYSA-N 1-(5-butoxypyridin-3-yl)-8-[(4-fluoropiperidin-1-yl)methyl]-4-methyl-[1,2,4]triazolo[4,3-a]quinoxaline Chemical compound CCCCOC1=CN=CC(C=2N3C4=CC(CN5CCC(F)CC5)=CC=C4N=C(C)C3=NN=2)=C1 ATLVGHFNDQLLKU-UHFFFAOYSA-N 0.000 description 1
- SULXBCRYOCJQQR-UHFFFAOYSA-N 1-(5-butoxypyridin-3-yl)-8-ethenyl-4-methyl-[1,2,4]triazolo[4,3-a]quinoxaline Chemical compound CCCCOC1=CN=CC(C=2N3C4=CC(C=C)=CC=C4N=C(C)C3=NN=2)=C1 SULXBCRYOCJQQR-UHFFFAOYSA-N 0.000 description 1
- AJSPTCIXWPDZQS-UHFFFAOYSA-N 1-(5-chloropyridin-3-yl)-4-methyl-[1,2,4]triazolo[4,3-a]quinoxaline Chemical compound N=1N=C2C(C)=NC3=CC=CC=C3N2C=1C1=CN=CC(Cl)=C1 AJSPTCIXWPDZQS-UHFFFAOYSA-N 0.000 description 1
- IGMOOVLKWXSJFK-UHFFFAOYSA-N 1-(5-methoxypyridin-3-yl)-4-methyl-8-(trifluoromethoxy)-[1,2,4]triazolo[4,3-a]quinoxaline Chemical compound COC1=CN=CC(C=2N3C4=CC(OC(F)(F)F)=CC=C4N=C(C)C3=NN=2)=C1 IGMOOVLKWXSJFK-UHFFFAOYSA-N 0.000 description 1
- CDCGFCNQTVJYFL-UHFFFAOYSA-N 1-(5-methoxypyridin-3-yl)-4-methyl-8-(trifluoromethyl)-[1,2,4]triazolo[4,3-a]quinoxaline Chemical compound COC1=CN=CC(C=2N3C4=CC(=CC=C4N=C(C)C3=NN=2)C(F)(F)F)=C1 CDCGFCNQTVJYFL-UHFFFAOYSA-N 0.000 description 1
- NDAIEAHJBPRDFW-UHFFFAOYSA-N 1-[1-(2-chloro-5-ethoxyphenyl)-4-methyl-[1,2,4]triazolo[4,3-a]quinoxalin-8-yl]-n,n-dimethylmethanamine Chemical compound CCOC1=CC=C(Cl)C(C=2N3C4=CC(CN(C)C)=CC=C4N=C(C)C3=NN=2)=C1 NDAIEAHJBPRDFW-UHFFFAOYSA-N 0.000 description 1
- VMGBREZRTHHNMB-UHFFFAOYSA-N 1-[1-(2-chloro-5-propan-2-yloxyphenyl)-4-methyl-[1,2,4]triazolo[4,3-a]quinoxalin-8-yl]-n,n-dimethylmethanamine Chemical compound CC(C)OC1=CC=C(Cl)C(C=2N3C4=CC(CN(C)C)=CC=C4N=C(C)C3=NN=2)=C1 VMGBREZRTHHNMB-UHFFFAOYSA-N 0.000 description 1
- BLJXRMKAAJLGJY-UHFFFAOYSA-N 1-[1-(2-chloro-5-propoxyphenyl)-4-methyl-[1,2,4]triazolo[4,3-a]quinoxalin-8-yl]-n,n-dimethylmethanamine Chemical compound CCCOC1=CC=C(Cl)C(C=2N3C4=CC(CN(C)C)=CC=C4N=C(C)C3=NN=2)=C1 BLJXRMKAAJLGJY-UHFFFAOYSA-N 0.000 description 1
- KTLGKXZSYXVVBQ-UHFFFAOYSA-N 1-[1-(2-chlorophenyl)-4-methyl-[1,2,4]triazolo[4,3-a]quinoxalin-8-yl]-2,2,2-trifluoroethanol Chemical compound N=1N=C2C(C)=NC3=CC=C(C(O)C(F)(F)F)C=C3N2C=1C1=CC=CC=C1Cl KTLGKXZSYXVVBQ-UHFFFAOYSA-N 0.000 description 1
- XEABXHPHIWCPSN-UHFFFAOYSA-N 1-[1-(2-chlorophenyl)-4-methyl-[1,2,4]triazolo[4,3-a]quinoxalin-8-yl]-n,n-dimethylmethanamine Chemical compound N12C3=CC(CN(C)C)=CC=C3N=C(C)C2=NN=C1C1=CC=CC=C1Cl XEABXHPHIWCPSN-UHFFFAOYSA-N 0.000 description 1
- HBHNASZPIMMBSP-UHFFFAOYSA-N 1-[1-(2-chlorophenyl)-4-methyl-[1,2,4]triazolo[4,3-a]quinoxalin-8-yl]-n-ethyl-2,2,2-trifluoroethanamine Chemical compound N12C3=CC(C(NCC)C(F)(F)F)=CC=C3N=C(C)C2=NN=C1C1=CC=CC=C1Cl HBHNASZPIMMBSP-UHFFFAOYSA-N 0.000 description 1
- LFPMUKYZLLOJCK-UHFFFAOYSA-N 1-[1-(5-butoxy-2-chlorophenyl)-4-methyl-[1,2,4]triazolo[4,3-a]quinoxalin-8-yl]-n,n-dimethylmethanamine Chemical compound CCCCOC1=CC=C(Cl)C(C=2N3C4=CC(CN(C)C)=CC=C4N=C(C)C3=NN=2)=C1 LFPMUKYZLLOJCK-UHFFFAOYSA-N 0.000 description 1
- SRNXYBWTUXBFQS-UHFFFAOYSA-N 1-[1-(5-butoxy-2-chlorophenyl)-4-methyl-[1,2,4]triazolo[4,3-a]quinoxalin-8-yl]-n-methylmethanamine Chemical compound CCCCOC1=CC=C(Cl)C(C=2N3C4=CC(CNC)=CC=C4N=C(C)C3=NN=2)=C1 SRNXYBWTUXBFQS-UHFFFAOYSA-N 0.000 description 1
- BXZOMMFMRNCLGL-UHFFFAOYSA-N 1-[1-(5-butoxypyridin-3-yl)-4-methyl-[1,2,4]triazolo[4,3-a]quinoxalin-8-yl]-n,n-dimethylmethanamine Chemical compound CCCCOC1=CN=CC(C=2N3C4=CC(CN(C)C)=CC=C4N=C(C)C3=NN=2)=C1 BXZOMMFMRNCLGL-UHFFFAOYSA-N 0.000 description 1
- YGIXIOXEHQAKBB-UHFFFAOYSA-N 1-[1-(5-butoxypyridin-3-yl)-4-methyl-[1,2,4]triazolo[4,3-a]quinoxalin-8-yl]-n-methylmethanamine Chemical compound CCCCOC1=CN=CC(C=2N3C4=CC(CNC)=CC=C4N=C(C)C3=NN=2)=C1 YGIXIOXEHQAKBB-UHFFFAOYSA-N 0.000 description 1
- KDLJETKCCNQONU-UHFFFAOYSA-N 1-[1-[5-(cyclopropylmethoxy)pyridin-3-yl]-4-methyl-[1,2,4]triazolo[4,3-a]quinoxalin-8-yl]-n,n-dimethylmethanamine Chemical compound N12C3=CC(CN(C)C)=CC=C3N=C(C)C2=NN=C1C(C=1)=CN=CC=1OCC1CC1 KDLJETKCCNQONU-UHFFFAOYSA-N 0.000 description 1
- GCDYIBKSDWHAEM-UHFFFAOYSA-N 1-[5-(cyclopropylmethoxy)pyridin-3-yl]-4-methyl-8-(pyrrolidin-1-ylmethyl)-[1,2,4]triazolo[4,3-a]quinoxaline Chemical compound C1=C2N3C(C=4C=C(OCC5CC5)C=NC=4)=NN=C3C(C)=NC2=CC=C1CN1CCCC1 GCDYIBKSDWHAEM-UHFFFAOYSA-N 0.000 description 1
- GBHVIGQENJZEGX-UHFFFAOYSA-N 1-[[1-(2-chloro-5-ethoxyphenyl)-4-methyl-[1,2,4]triazolo[4,3-a]quinoxalin-8-yl]methyl]piperidin-4-ol Chemical compound CCOC1=CC=C(Cl)C(C=2N3C4=CC(CN5CCC(O)CC5)=CC=C4N=C(C)C3=NN=2)=C1 GBHVIGQENJZEGX-UHFFFAOYSA-N 0.000 description 1
- UNICJUYOQQVHAZ-UHFFFAOYSA-N 1-[[1-(2-chloro-5-propan-2-yloxyphenyl)-4-methyl-[1,2,4]triazolo[4,3-a]quinoxalin-8-yl]methyl]piperidin-4-ol Chemical compound CC(C)OC1=CC=C(Cl)C(C=2N3C4=CC(CN5CCC(O)CC5)=CC=C4N=C(C)C3=NN=2)=C1 UNICJUYOQQVHAZ-UHFFFAOYSA-N 0.000 description 1
- CBYKYFOMDUTGTG-UHFFFAOYSA-N 1-[[1-(2-chlorophenyl)-4-methyl-[1,2,4]triazolo[4,3-a]quinoxalin-8-yl]methyl]-n,n-dimethylpiperidin-4-amine Chemical compound C1CC(N(C)C)CCN1CC1=CC=C(N=C(C)C=2N3C(C=4C(=CC=CC=4)Cl)=NN=2)C3=C1 CBYKYFOMDUTGTG-UHFFFAOYSA-N 0.000 description 1
- YCWMKHFHOBOJHS-UHFFFAOYSA-N 1-[[1-(2-chlorophenyl)-4-methyl-[1,2,4]triazolo[4,3-a]quinoxalin-8-yl]methyl]piperidin-3-ol Chemical compound C1=C2N3C(C=4C(=CC=CC=4)Cl)=NN=C3C(C)=NC2=CC=C1CN1CCCC(O)C1 YCWMKHFHOBOJHS-UHFFFAOYSA-N 0.000 description 1
- OIOIOFDJPMGWSE-UHFFFAOYSA-N 1-[[1-(2-chlorophenyl)-4-methyl-[1,2,4]triazolo[4,3-a]quinoxalin-8-yl]methyl]piperidin-4-ol Chemical compound C1=C2N3C(C=4C(=CC=CC=4)Cl)=NN=C3C(C)=NC2=CC=C1CN1CCC(O)CC1 OIOIOFDJPMGWSE-UHFFFAOYSA-N 0.000 description 1
- JLLMMQQXVRIGOZ-UHFFFAOYSA-N 1-[[1-(2-chlorophenyl)-4-methyl-[1,2,4]triazolo[4,3-a]quinoxalin-8-yl]methyl]pyrrolidin-3-ol Chemical compound C1=C2N3C(C=4C(=CC=CC=4)Cl)=NN=C3C(C)=NC2=CC=C1CN1CCC(O)C1 JLLMMQQXVRIGOZ-UHFFFAOYSA-N 0.000 description 1
- FSCIQUOKFKVFRY-UHFFFAOYSA-N 1-[[1-(5-butoxy-2-chlorophenyl)-4-methyl-[1,2,4]triazolo[4,3-a]quinoxalin-8-yl]methyl]piperidin-4-ol Chemical compound CCCCOC1=CC=C(Cl)C(C=2N3C4=CC(CN5CCC(O)CC5)=CC=C4N=C(C)C3=NN=2)=C1 FSCIQUOKFKVFRY-UHFFFAOYSA-N 0.000 description 1
- KFTLKVVMSXUDGJ-UHFFFAOYSA-N 2-phenylethyl 4-methyl-1-phenyl-[1,2,4]triazolo[4,3-a]quinoxaline-8-carboxylate Chemical compound N=1N=C2C(C)=NC3=CC=C(C(=O)OCCC=4C=CC=CC=4)C=C3N2C=1C1=CC=CC=C1 KFTLKVVMSXUDGJ-UHFFFAOYSA-N 0.000 description 1
- SGHKMBWVNBLMNC-UHFFFAOYSA-N 3-phenylpropyl 4-methyl-1-phenyl-[1,2,4]triazolo[4,3-a]quinoxaline-8-carboxylate Chemical compound N=1N=C2C(C)=NC3=CC=C(C(=O)OCCCC=4C=CC=CC=4)C=C3N2C=1C1=CC=CC=C1 SGHKMBWVNBLMNC-UHFFFAOYSA-N 0.000 description 1
- PDOPFYRTIVSUKL-UHFFFAOYSA-N 4-(azepan-1-yl)-[1,2,4]triazolo[4,3-a]quinoxaline Chemical compound C1CCCCCN1C1=NC2=CC=CC=C2N2C1=NN=C2 PDOPFYRTIVSUKL-UHFFFAOYSA-N 0.000 description 1
- LNWOPNAAKIWAGD-UHFFFAOYSA-N 4-[1-[1-(2-chlorophenyl)-4-methyl-[1,2,4]triazolo[4,3-a]quinoxalin-8-yl]-2,2,2-trifluoroethyl]morpholine Chemical compound N=1N=C2C(C)=NC3=CC=C(C(N4CCOCC4)C(F)(F)F)C=C3N2C=1C1=CC=CC=C1Cl LNWOPNAAKIWAGD-UHFFFAOYSA-N 0.000 description 1
- HNVOBUPJZXUUSK-UHFFFAOYSA-N 4-[2-[[1-(2-chlorophenyl)-4-methyl-[1,2,4]triazolo[4,3-a]quinoxalin-8-yl]oxy]ethyl]morpholine Chemical compound C1=C2N3C(C=4C(=CC=CC=4)Cl)=NN=C3C(C)=NC2=CC=C1OCCN1CCOCC1 HNVOBUPJZXUUSK-UHFFFAOYSA-N 0.000 description 1
- VXJBJRPOPQUACF-UHFFFAOYSA-N 4-[[1-(2-chloro-4-fluorophenyl)-4-methyl-[1,2,4]triazolo[4,3-a]quinoxalin-8-yl]methyl]morpholine Chemical compound C1=C2N3C(C=4C(=CC(F)=CC=4)Cl)=NN=C3C(C)=NC2=CC=C1CN1CCOCC1 VXJBJRPOPQUACF-UHFFFAOYSA-N 0.000 description 1
- PQYOTCFMIISAPG-UHFFFAOYSA-N 4-[[1-(2-chloro-5-ethoxyphenyl)-4-methyl-[1,2,4]triazolo[4,3-a]quinoxalin-8-yl]methyl]morpholine Chemical compound CCOC1=CC=C(Cl)C(C=2N3C4=CC(CN5CCOCC5)=CC=C4N=C(C)C3=NN=2)=C1 PQYOTCFMIISAPG-UHFFFAOYSA-N 0.000 description 1
- VDIAEIJDVYOMLE-UHFFFAOYSA-N 4-[[1-(2-chloro-5-methoxyphenyl)-4-methyl-[1,2,4]triazolo[4,3-a]quinoxalin-8-yl]methyl]morpholine Chemical compound COC1=CC=C(Cl)C(C=2N3C4=CC(CN5CCOCC5)=CC=C4N=C(C)C3=NN=2)=C1 VDIAEIJDVYOMLE-UHFFFAOYSA-N 0.000 description 1
- JBSVWNORKAJZAE-UHFFFAOYSA-N 4-[[1-(2-chloro-5-propan-2-yloxyphenyl)-4-methyl-[1,2,4]triazolo[4,3-a]quinoxalin-8-yl]methyl]morpholine Chemical compound CC(C)OC1=CC=C(Cl)C(C=2N3C4=CC(CN5CCOCC5)=CC=C4N=C(C)C3=NN=2)=C1 JBSVWNORKAJZAE-UHFFFAOYSA-N 0.000 description 1
- AFHVGEIXWXGUNT-UHFFFAOYSA-N 4-[[1-(2-chloro-5-propoxyphenyl)-4-methyl-[1,2,4]triazolo[4,3-a]quinoxalin-8-yl]methyl]morpholine Chemical compound CCCOC1=CC=C(Cl)C(C=2N3C4=CC(CN5CCOCC5)=CC=C4N=C(C)C3=NN=2)=C1 AFHVGEIXWXGUNT-UHFFFAOYSA-N 0.000 description 1
- BXKLAYQKTVKJCY-VNRZBHCFSA-N 4-[[1-(2-chloro-6-fluoranylphenyl)-4-methyl-[1,2,4]triazolo[4,3-a]quinoxalin-8-yl]methyl]morpholine Chemical compound C1=C2N3C(C=4C(=CC=CC=4[18F])Cl)=NN=C3C(C)=NC2=CC=C1CN1CCOCC1 BXKLAYQKTVKJCY-VNRZBHCFSA-N 0.000 description 1
- BXKLAYQKTVKJCY-UHFFFAOYSA-N 4-[[1-(2-chloro-6-fluorophenyl)-4-methyl-[1,2,4]triazolo[4,3-a]quinoxalin-8-yl]methyl]morpholine Chemical compound C1=C2N3C(C=4C(=CC=CC=4F)Cl)=NN=C3C(C)=NC2=CC=C1CN1CCOCC1 BXKLAYQKTVKJCY-UHFFFAOYSA-N 0.000 description 1
- INCSVUYCNVZRDA-UHFFFAOYSA-N 4-[[1-(2-chlorophenyl)-4-methyl-[1,2,4]triazolo[4,3-a]quinoxalin-8-yl]methyl]-2-(2-fluoroethyl)morpholine Chemical compound C1=C2N3C(C=4C(=CC=CC=4)Cl)=NN=C3C(C)=NC2=CC=C1CN1CCOC(CCF)C1 INCSVUYCNVZRDA-UHFFFAOYSA-N 0.000 description 1
- APEPKKHCYXRSQK-UHFFFAOYSA-N 4-[[1-(2-chlorophenyl)-4-methyl-[1,2,4]triazolo[4,3-a]quinoxalin-8-yl]methyl]-2-(2-methoxyethyl)morpholine Chemical compound C1COC(CCOC)CN1CC1=CC=C(N=C(C)C=2N3C(C=4C(=CC=CC=4)Cl)=NN=2)C3=C1 APEPKKHCYXRSQK-UHFFFAOYSA-N 0.000 description 1
- ZQQQCGMZTQYBOM-UHFFFAOYSA-N 4-[[1-(2-chlorophenyl)-4-methyl-[1,2,4]triazolo[4,3-a]quinoxalin-8-yl]methyl]-2-(fluoromethyl)morpholine Chemical compound C1=C2N3C(C=4C(=CC=CC=4)Cl)=NN=C3C(C)=NC2=CC=C1CN1CCOC(CF)C1 ZQQQCGMZTQYBOM-UHFFFAOYSA-N 0.000 description 1
- BDTNXPSVJKURRR-UHFFFAOYSA-N 4-[[1-(2-chlorophenyl)-4-methyl-[1,2,4]triazolo[4,3-a]quinoxalin-8-yl]methyl]-2-(methoxymethyl)morpholine Chemical compound C1COC(COC)CN1CC1=CC=C(N=C(C)C=2N3C(C=4C(=CC=CC=4)Cl)=NN=2)C3=C1 BDTNXPSVJKURRR-UHFFFAOYSA-N 0.000 description 1
- LHZOEXXQXFAFRU-UHFFFAOYSA-N 4-[[1-(2-chlorophenyl)-4-methyl-[1,2,4]triazolo[4,3-a]quinoxalin-8-yl]methyl]-2-fluoro-2-(trifluoromethyl)morpholine Chemical compound C1=C2N3C(C=4C(=CC=CC=4)Cl)=NN=C3C(C)=NC2=CC=C1CN1CCOC(F)(C(F)(F)F)C1 LHZOEXXQXFAFRU-UHFFFAOYSA-N 0.000 description 1
- LZRGPVBUCASWQB-UHFFFAOYSA-N 4-[[1-(2-chlorophenyl)-4-methyl-[1,2,4]triazolo[4,3-a]quinoxalin-8-yl]methyl]morpholine Chemical compound C1=C2N3C(C=4C(=CC=CC=4)Cl)=NN=C3C(C)=NC2=CC=C1CN1CCOCC1 LZRGPVBUCASWQB-UHFFFAOYSA-N 0.000 description 1
- GSHAVWDELPHUJH-UHFFFAOYSA-N 4-[[1-(5-butoxy-2-chlorophenyl)-4-methyl-[1,2,4]triazolo[4,3-a]quinoxalin-8-yl]methyl]morpholine Chemical compound CCCCOC1=CC=C(Cl)C(C=2N3C4=CC(CN5CCOCC5)=CC=C4N=C(C)C3=NN=2)=C1 GSHAVWDELPHUJH-UHFFFAOYSA-N 0.000 description 1
- PKPRTWSDEQLHCM-UHFFFAOYSA-N 4-[[1-(5-butoxy-6-chloropyridin-3-yl)-4-methyl-[1,2,4]triazolo[4,3-a]quinoxalin-8-yl]methyl]morpholine Chemical compound N1=C(Cl)C(OCCCC)=CC(C=2N3C4=CC(CN5CCOCC5)=CC=C4N=C(C)C3=NN=2)=C1 PKPRTWSDEQLHCM-UHFFFAOYSA-N 0.000 description 1
- JJQZDOKXARNTKH-TZLORFPWSA-N 4-[[1-(5-butoxypyridin-3-yl)-4-methyl-[1,2,4]triazolo[4,3-a]quinoxalin-8-yl]-tritiomethyl]morpholine Chemical compound C=1C=C2N=C(C)C3=NN=C(C=4C=C(OCCCC)C=NC=4)N3C2=CC=1C([3H])N1CCOCC1 JJQZDOKXARNTKH-TZLORFPWSA-N 0.000 description 1
- JJQZDOKXARNTKH-UHFFFAOYSA-N 4-[[1-(5-butoxypyridin-3-yl)-4-methyl-[1,2,4]triazolo[4,3-a]quinoxalin-8-yl]methyl]morpholine Chemical compound CCCCOC1=CN=CC(C=2N3C4=CC(CN5CCOCC5)=CC=C4N=C(C)C3=NN=2)=C1 JJQZDOKXARNTKH-UHFFFAOYSA-N 0.000 description 1
- MUTVZBOSDNBOEV-UHFFFAOYSA-N 4-[[1-(5-methoxypyridin-3-yl)-4-methyl-[1,2,4]triazolo[4,3-a]quinoxalin-8-yl]methyl]morpholine Chemical compound COC1=CN=CC(C=2N3C4=CC(CN5CCOCC5)=CC=C4N=C(C)C3=NN=2)=C1 MUTVZBOSDNBOEV-UHFFFAOYSA-N 0.000 description 1
- NNSOUHQDSQHDRT-UHFFFAOYSA-N 4-[[1-[5-(2-fluoroethoxy)pyridin-3-yl]-4-methyl-[1,2,4]triazolo[4,3-a]quinoxalin-8-yl]methyl]morpholine Chemical compound C1=C2N3C(C=4C=C(OCCF)C=NC=4)=NN=C3C(C)=NC2=CC=C1CN1CCOCC1 NNSOUHQDSQHDRT-UHFFFAOYSA-N 0.000 description 1
- RBCNIKAFOHITAE-UHFFFAOYSA-N 4-[[1-[5-(2-methoxyethoxy)pyridin-3-yl]-4-methyl-[1,2,4]triazolo[4,3-a]quinoxalin-8-yl]methyl]morpholine Chemical compound COCCOC1=CN=CC(C=2N3C4=CC(CN5CCOCC5)=CC=C4N=C(C)C3=NN=2)=C1 RBCNIKAFOHITAE-UHFFFAOYSA-N 0.000 description 1
- TYTYHDPELCLVBA-UHFFFAOYSA-N 4-[[1-[5-(3-fluoropropoxy)pyridin-3-yl]-4-methyl-[1,2,4]triazolo[4,3-a]quinoxalin-8-yl]methyl]morpholine Chemical compound C1=C2N3C(C=4C=C(OCCCF)C=NC=4)=NN=C3C(C)=NC2=CC=C1CN1CCOCC1 TYTYHDPELCLVBA-UHFFFAOYSA-N 0.000 description 1
- GYCAHBYJOXOETE-UHFFFAOYSA-N 4-[[1-[5-(3-methoxypropyl)pyridin-3-yl]-4-methyl-[1,2,4]triazolo[4,3-a]quinoxalin-8-yl]methyl]morpholine Chemical compound COCCCC1=CN=CC(C=2N3C4=CC(CN5CCOCC5)=CC=C4N=C(C)C3=NN=2)=C1 GYCAHBYJOXOETE-UHFFFAOYSA-N 0.000 description 1
- ULBXWWOIYQZKIK-UHFFFAOYSA-N 4-[[1-[5-(ethoxymethyl)pyridin-3-yl]-4-methyl-[1,2,4]triazolo[4,3-a]quinoxalin-8-yl]methyl]morpholine Chemical compound CCOCC1=CN=CC(C=2N3C4=CC(CN5CCOCC5)=CC=C4N=C(C)C3=NN=2)=C1 ULBXWWOIYQZKIK-UHFFFAOYSA-N 0.000 description 1
- TVELNZSUPLTMOH-UHFFFAOYSA-N 4-[[4-methyl-1-(2-methylpyridin-3-yl)-[1,2,4]triazolo[4,3-a]quinoxalin-8-yl]methyl]morpholine Chemical compound CC1=NC=CC=C1C1=NN=C2N1C1=CC(CN3CCOCC3)=CC=C1N=C2C TVELNZSUPLTMOH-UHFFFAOYSA-N 0.000 description 1
- RXQBGBZOHKWYBQ-UHFFFAOYSA-N 4-[[4-methyl-1-(5-propoxypyridin-3-yl)-[1,2,4]triazolo[4,3-a]quinoxalin-8-yl]methyl]morpholine Chemical compound CCCOC1=CN=CC(C=2N3C4=CC(CN5CCOCC5)=CC=C4N=C(C)C3=NN=2)=C1 RXQBGBZOHKWYBQ-UHFFFAOYSA-N 0.000 description 1
- OSPAOFOZCVPMQA-UHFFFAOYSA-N 4-methyl-1-(2-methylpyridin-3-yl)-8-(trifluoromethoxy)-[1,2,4]triazolo[4,3-a]quinoxaline Chemical compound CC1=NC=CC=C1C1=NN=C2N1C1=CC(OC(F)(F)F)=CC=C1N=C2C OSPAOFOZCVPMQA-UHFFFAOYSA-N 0.000 description 1
- WJMGAKGFRQIMSW-UHFFFAOYSA-N 4-methyl-1-(2-methylpyridin-3-yl)-8-(trifluoromethyl)-[1,2,4]triazolo[4,3-a]quinoxaline Chemical compound CC1=NC=CC=C1C1=NN=C2N1C1=CC(C(F)(F)F)=CC=C1N=C2C WJMGAKGFRQIMSW-UHFFFAOYSA-N 0.000 description 1
- MNWBTFJCPUFSLK-UHFFFAOYSA-N 4-methyl-1-(2-methylpyridin-3-yl)-[1,2,4]triazolo[4,3-a]quinoxaline Chemical compound CC1=NC=CC=C1C1=NN=C2N1C1=CC=CC=C1N=C2C MNWBTFJCPUFSLK-UHFFFAOYSA-N 0.000 description 1
- ITHFELWCNWJUJU-UHFFFAOYSA-N 4-methyl-1-(5-methylpyridin-3-yl)-8-(trifluoromethyl)-[1,2,4]triazolo[4,3-a]quinoxaline Chemical compound CC1=CN=CC(C=2N3C4=CC(=CC=C4N=C(C)C3=NN=2)C(F)(F)F)=C1 ITHFELWCNWJUJU-UHFFFAOYSA-N 0.000 description 1
- STFUEDUBXBUOOF-UHFFFAOYSA-N 4-methyl-1-(5-methylpyridin-3-yl)-[1,2,4]triazolo[4,3-a]quinoxaline Chemical compound CC1=CN=CC(C=2N3C4=CC=CC=C4N=C(C)C3=NN=2)=C1 STFUEDUBXBUOOF-UHFFFAOYSA-N 0.000 description 1
- RJLICWCTMWNDHQ-UHFFFAOYSA-N 4-methyl-1-phenyl-[1,2,4]triazolo[4,3-a]quinoxaline-8-carboxylic acid Chemical compound N=1N=C2C(C)=NC3=CC=C(C(O)=O)C=C3N2C=1C1=CC=CC=C1 RJLICWCTMWNDHQ-UHFFFAOYSA-N 0.000 description 1
- ZFULJVQXYCCNKE-UHFFFAOYSA-N 4-methyl-1-phenyl-n-(2-phenylethyl)-[1,2,4]triazolo[4,3-a]quinoxaline-8-carboxamide Chemical compound N=1N=C2C(C)=NC3=CC=C(C(=O)NCCC=4C=CC=CC=4)C=C3N2C=1C1=CC=CC=C1 ZFULJVQXYCCNKE-UHFFFAOYSA-N 0.000 description 1
- FBLAQBPJSVGFII-UHFFFAOYSA-N 4-methyl-1-phenyl-n-(3-phenylpropyl)-[1,2,4]triazolo[4,3-a]quinoxaline-8-carboxamide Chemical compound N=1N=C2C(C)=NC3=CC=C(C(=O)NCCCC=4C=CC=CC=4)C=C3N2C=1C1=CC=CC=C1 FBLAQBPJSVGFII-UHFFFAOYSA-N 0.000 description 1
- MWOGXMHCBKOPQQ-UHFFFAOYSA-N 4-methyl-1-phenyl-n-(pyridin-2-ylmethyl)-[1,2,4]triazolo[4,3-a]quinoxaline-8-carboxamide Chemical compound N=1N=C2C(C)=NC3=CC=C(C(=O)NCC=4N=CC=CC=4)C=C3N2C=1C1=CC=CC=C1 MWOGXMHCBKOPQQ-UHFFFAOYSA-N 0.000 description 1
- QYYMHMXTKXJDBS-UHFFFAOYSA-N 4-methyl-1-phenyl-n-(pyridin-3-ylmethyl)-[1,2,4]triazolo[4,3-a]quinoxaline-8-carboxamide Chemical compound N=1N=C2C(C)=NC3=CC=C(C(=O)NCC=4C=NC=CC=4)C=C3N2C=1C1=CC=CC=C1 QYYMHMXTKXJDBS-UHFFFAOYSA-N 0.000 description 1
- BLGZTKFEGIQNDY-UHFFFAOYSA-N 4-methyl-1-phenyl-n-(pyridin-4-ylmethyl)-[1,2,4]triazolo[4,3-a]quinoxaline-8-carboxamide Chemical compound N=1N=C2C(C)=NC3=CC=C(C(=O)NCC=4C=CN=CC=4)C=C3N2C=1C1=CC=CC=C1 BLGZTKFEGIQNDY-UHFFFAOYSA-N 0.000 description 1
- HYZRBWOMKBCLRS-UHFFFAOYSA-N 4-methyl-8-(phenoxymethyl)-1-phenyl-[1,2,4]triazolo[4,3-a]quinoxaline Chemical compound C1=C2N3C(C=4C=CC=CC=4)=NN=C3C(C)=NC2=CC=C1COC1=CC=CC=C1 HYZRBWOMKBCLRS-UHFFFAOYSA-N 0.000 description 1
- KNRNBEGUVDNLBV-UHFFFAOYSA-N 7-bromo-1-(2-chlorophenyl)-4-methyl-[1,2,4]triazolo[4,3-a]quinoxaline Chemical compound N=1N=C2C(C)=NC3=CC(Br)=CC=C3N2C=1C1=CC=CC=C1Cl KNRNBEGUVDNLBV-UHFFFAOYSA-N 0.000 description 1
- UPDIRNSYQOPJKU-UHFFFAOYSA-N 7-bromo-1-(5-butoxy-2-chlorophenyl)-4-methyl-[1,2,4]triazolo[4,3-a]quinoxaline Chemical compound CCCCOC1=CC=C(Cl)C(C=2N3C4=CC=C(Br)C=C4N=C(C)C3=NN=2)=C1 UPDIRNSYQOPJKU-UHFFFAOYSA-N 0.000 description 1
- OUEVIWDWCUUCHD-UHFFFAOYSA-N 7-bromo-1-(5-butoxy-2-fluorophenyl)-4-methyl-[1,2,4]triazolo[4,3-a]quinoxaline Chemical compound CCCCOC1=CC=C(F)C(C=2N3C4=CC=C(Br)C=C4N=C(C)C3=NN=2)=C1 OUEVIWDWCUUCHD-UHFFFAOYSA-N 0.000 description 1
- CQZCPEJZRTXMSW-UHFFFAOYSA-N 8-(ethoxymethyl)-4-methyl-1-phenyl-[1,2,4]triazolo[4,3-a]quinoxaline Chemical compound N12C3=CC(COCC)=CC=C3N=C(C)C2=NN=C1C1=CC=CC=C1 CQZCPEJZRTXMSW-UHFFFAOYSA-N 0.000 description 1
- YBKHCZWQDPUACZ-UHFFFAOYSA-N 8-bromo-1-(2,3-dichlorophenyl)-4-methyl-[1,2,4]triazolo[4,3-a]quinoxaline Chemical compound N=1N=C2C(C)=NC3=CC=C(Br)C=C3N2C=1C1=CC=CC(Cl)=C1Cl YBKHCZWQDPUACZ-UHFFFAOYSA-N 0.000 description 1
- NUXISPFRNTYOGK-UHFFFAOYSA-N 8-bromo-1-(2,5-dichlorophenyl)-4-methyl-[1,2,4]triazolo[4,3-a]quinoxaline Chemical compound N=1N=C2C(C)=NC3=CC=C(Br)C=C3N2C=1C1=CC(Cl)=CC=C1Cl NUXISPFRNTYOGK-UHFFFAOYSA-N 0.000 description 1
- ZDIJUOBOIDUBPE-UHFFFAOYSA-N 8-bromo-1-(2-chloro-5-ethoxyphenyl)-4-methyl-[1,2,4]triazolo[4,3-a]quinoxaline Chemical compound CCOC1=CC=C(Cl)C(C=2N3C4=CC(Br)=CC=C4N=C(C)C3=NN=2)=C1 ZDIJUOBOIDUBPE-UHFFFAOYSA-N 0.000 description 1
- XRZVFFZEPRUUNF-UHFFFAOYSA-N 8-bromo-1-(2-chloro-5-methoxyphenyl)-4-methyl-[1,2,4]triazolo[4,3-a]quinoxaline Chemical compound COC1=CC=C(Cl)C(C=2N3C4=CC(Br)=CC=C4N=C(C)C3=NN=2)=C1 XRZVFFZEPRUUNF-UHFFFAOYSA-N 0.000 description 1
- FEZMGTPFCMFBNJ-UHFFFAOYSA-N 8-bromo-1-(2-chloro-5-propoxyphenyl)-4-methyl-[1,2,4]triazolo[4,3-a]quinoxaline Chemical compound CCCOC1=CC=C(Cl)C(C=2N3C4=CC(Br)=CC=C4N=C(C)C3=NN=2)=C1 FEZMGTPFCMFBNJ-UHFFFAOYSA-N 0.000 description 1
- HCIYBDDFKIFQGZ-UHFFFAOYSA-N 8-bromo-1-(2-chloro-6-fluorophenyl)-4-methyl-[1,2,4]triazolo[4,3-a]quinoxaline Chemical compound N=1N=C2C(C)=NC3=CC=C(Br)C=C3N2C=1C1=C(F)C=CC=C1Cl HCIYBDDFKIFQGZ-UHFFFAOYSA-N 0.000 description 1
- DQPTWPRWYXHDGO-UHFFFAOYSA-N 8-bromo-1-(2-chlorophenyl)-4-methyl-[1,2,4]triazolo[4,3-a]quinoxaline Chemical compound N=1N=C2C(C)=NC3=CC=C(Br)C=C3N2C=1C1=CC=CC=C1Cl DQPTWPRWYXHDGO-UHFFFAOYSA-N 0.000 description 1
- SFIXGLDTGNYPBL-UHFFFAOYSA-N 8-bromo-1-(5-butoxy-2-chlorophenyl)-4-methyl-[1,2,4]triazolo[4,3-a]quinoxaline Chemical compound CCCCOC1=CC=C(Cl)C(C=2N3C4=CC(Br)=CC=C4N=C(C)C3=NN=2)=C1 SFIXGLDTGNYPBL-UHFFFAOYSA-N 0.000 description 1
- PQXINFPHBGOGGU-UHFFFAOYSA-N 8-bromo-1-(5-butoxy-2-fluorophenyl)-4-methyl-[1,2,4]triazolo[4,3-a]quinoxaline Chemical compound CCCCOC1=CC=C(F)C(C=2N3C4=CC(Br)=CC=C4N=C(C)C3=NN=2)=C1 PQXINFPHBGOGGU-UHFFFAOYSA-N 0.000 description 1
- AUJUNLOZUFGEGD-UHFFFAOYSA-N 8-bromo-1-(5-butoxypyridin-3-yl)-4-methyl-[1,2,4]triazolo[4,3-a]quinoxaline Chemical compound CCCCOC1=CN=CC(C=2N3C4=CC(Br)=CC=C4N=C(C)C3=NN=2)=C1 AUJUNLOZUFGEGD-UHFFFAOYSA-N 0.000 description 1
- XHXPLDYBXUYOHZ-UHFFFAOYSA-N 8-bromo-1-(5-chloropyridin-3-yl)-4-methyl-[1,2,4]triazolo[4,3-a]quinoxaline Chemical compound N=1N=C2C(C)=NC3=CC=C(Br)C=C3N2C=1C1=CN=CC(Cl)=C1 XHXPLDYBXUYOHZ-UHFFFAOYSA-N 0.000 description 1
- VTCJWGQRODMDTE-UHFFFAOYSA-N 8-bromo-1-(5-methoxypyridin-3-yl)-4-methyl-[1,2,4]triazolo[4,3-a]quinoxaline Chemical compound COC1=CN=CC(C=2N3C4=CC(Br)=CC=C4N=C(C)C3=NN=2)=C1 VTCJWGQRODMDTE-UHFFFAOYSA-N 0.000 description 1
- CLDKFVHULZSNMB-UHFFFAOYSA-N 8-bromo-1-[5-(cyclopropylmethoxy)pyridin-3-yl]-4-methyl-[1,2,4]triazolo[4,3-a]quinoxaline Chemical compound N=1N=C2C(C)=NC3=CC=C(Br)C=C3N2C=1C(C=1)=CN=CC=1OCC1CC1 CLDKFVHULZSNMB-UHFFFAOYSA-N 0.000 description 1
- YAMSWNBYZYOMKC-UHFFFAOYSA-N 8-bromo-4-methyl-1-(2-methylpyridin-3-yl)-[1,2,4]triazolo[4,3-a]quinoxaline Chemical compound CC1=NC=CC=C1C1=NN=C2N1C1=CC(Br)=CC=C1N=C2C YAMSWNBYZYOMKC-UHFFFAOYSA-N 0.000 description 1
- RYSNNCCSSIJKTQ-UHFFFAOYSA-N 8-bromo-4-methyl-1-(4-methylpyridin-3-yl)-[1,2,4]triazolo[4,3-a]quinoxaline Chemical compound CC1=CC=NC=C1C1=NN=C2N1C1=CC(Br)=CC=C1N=C2C RYSNNCCSSIJKTQ-UHFFFAOYSA-N 0.000 description 1
- ZQZQJSNJBXJBRY-UHFFFAOYSA-N 8-bromo-4-methyl-1-(5-methylpyridin-3-yl)-[1,2,4]triazolo[4,3-a]quinoxaline Chemical compound CC1=CN=CC(C=2N3C4=CC(Br)=CC=C4N=C(C)C3=NN=2)=C1 ZQZQJSNJBXJBRY-UHFFFAOYSA-N 0.000 description 1
- NTQZQHOTDALRDO-UHFFFAOYSA-N 8-bromo-4-methyl-1-[2-(trifluoromethoxy)phenyl]-[1,2,4]triazolo[4,3-a]quinoxaline Chemical compound N=1N=C2C(C)=NC3=CC=C(Br)C=C3N2C=1C1=CC=CC=C1OC(F)(F)F NTQZQHOTDALRDO-UHFFFAOYSA-N 0.000 description 1
- IDINXJHHFWOVFM-UHFFFAOYSA-N 8-ethenyl-4-methyl-1-(4-methylpyridin-3-yl)-[1,2,4]triazolo[4,3-a]quinoxaline Chemical compound CC1=CC=NC=C1C1=NN=C2N1C1=CC(C=C)=CC=C1N=C2C IDINXJHHFWOVFM-UHFFFAOYSA-N 0.000 description 1
- WEYXJGDVURKFSL-UHFFFAOYSA-N 8-methoxy-4-methyl-1-(4-methylpyridin-3-yl)-[1,2,4]triazolo[4,3-a]quinoxaline Chemical compound N12C3=CC(OC)=CC=C3N=C(C)C2=NN=C1C1=CN=CC=C1C WEYXJGDVURKFSL-UHFFFAOYSA-N 0.000 description 1
- HVHHDNVBEAWEKV-UHFFFAOYSA-N 8-methoxy-4-methyl-1-[2-(trifluoromethoxy)phenyl]-[1,2,4]triazolo[4,3-a]quinoxaline Chemical compound N12C3=CC(OC)=CC=C3N=C(C)C2=NN=C1C1=CC=CC=C1OC(F)(F)F HVHHDNVBEAWEKV-UHFFFAOYSA-N 0.000 description 1
- WWDJFTHPKCEQHD-UHFFFAOYSA-N CC(C1OCCN(CC2=CC=C3N=C(C)C4=NN=C(C(C=CC=C5)=C5Cl)N4C3=C2)C1)O Chemical compound CC(C1OCCN(CC2=CC=C3N=C(C)C4=NN=C(C(C=CC=C5)=C5Cl)N4C3=C2)C1)O WWDJFTHPKCEQHD-UHFFFAOYSA-N 0.000 description 1
- DXWWBWCVHBJEHK-UHFFFAOYSA-N CC1=NC2=C(C=C(C=C2)Br)N3C1=NN=C3C4=C(C=CC(=C4)OC(C)OC)Cl Chemical compound CC1=NC2=C(C=C(C=C2)Br)N3C1=NN=C3C4=C(C=CC(=C4)OC(C)OC)Cl DXWWBWCVHBJEHK-UHFFFAOYSA-N 0.000 description 1
- XUOKIWXOOWOOMQ-UHFFFAOYSA-N CC1=NC2=C(C=C(C=C2)OCCC3=CN=CC=C3)N4C1=NN=C4C5=C(C=CC(=C5)OC(C)OC)Cl Chemical compound CC1=NC2=C(C=C(C=C2)OCCC3=CN=CC=C3)N4C1=NN=C4C5=C(C=CC(=C5)OC(C)OC)Cl XUOKIWXOOWOOMQ-UHFFFAOYSA-N 0.000 description 1
- NBBZSTXSWIIWDK-QAQDUYKDSA-N ClC1=C(C=CC=C1)C1=NN=C2N1C1=CC(=CC=C1N=C2C)CN[C@@H]2CC[C@H](CC2)O Chemical compound ClC1=C(C=CC=C1)C1=NN=C2N1C1=CC(=CC=C1N=C2C)CN[C@@H]2CC[C@H](CC2)O NBBZSTXSWIIWDK-QAQDUYKDSA-N 0.000 description 1
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 1
- MRIRZVKWJQGRQV-UHFFFAOYSA-N [1-(2-chlorophenyl)-4-methyl-[1,2,4]triazolo[4,3-a]quinoxalin-8-yl]-cyclopropylmethanone Chemical compound N=1N=C2C(C)=NC3=CC=C(C(=O)C4CC4)C=C3N2C=1C1=CC=CC=C1Cl MRIRZVKWJQGRQV-UHFFFAOYSA-N 0.000 description 1
- XYHOTKZGFKCGHN-UHFFFAOYSA-N [1-[[1-(2-chlorophenyl)-4-methyl-[1,2,4]triazolo[4,3-a]quinoxalin-8-yl]methyl]piperidin-3-yl]methanol Chemical compound C1=C2N3C(C=4C(=CC=CC=4)Cl)=NN=C3C(C)=NC2=CC=C1CN1CCCC(CO)C1 XYHOTKZGFKCGHN-UHFFFAOYSA-N 0.000 description 1
- ZBQNRSUAPBSMFO-UHFFFAOYSA-N [4-[[1-(2-chlorophenyl)-4-methyl-[1,2,4]triazolo[4,3-a]quinoxalin-8-yl]methyl]morpholin-2-yl]methanol Chemical compound C1=C2N3C(C=4C(=CC=CC=4)Cl)=NN=C3C(C)=NC2=CC=C1CN1CCOC(CO)C1 ZBQNRSUAPBSMFO-UHFFFAOYSA-N 0.000 description 1
- NCGASUCQDDAREU-UHFFFAOYSA-N benzyl 4-methyl-1-phenyl-[1,2,4]triazolo[4,3-a]quinoxaline-8-carboxylate Chemical compound N=1N=C2C(C)=NC3=CC=C(C(=O)OCC=4C=CC=CC=4)C=C3N2C=1C1=CC=CC=C1 NCGASUCQDDAREU-UHFFFAOYSA-N 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- GFZOJSHVIDTDPC-UHFFFAOYSA-N cyclopropyl-[4-methyl-1-(4-methylpyridin-3-yl)-[1,2,4]triazolo[4,3-a]quinoxalin-8-yl]methanone Chemical compound CC1=CC=NC=C1C1=NN=C2N1C1=CC(C(=O)C3CC3)=CC=C1N=C2C GFZOJSHVIDTDPC-UHFFFAOYSA-N 0.000 description 1
- 125000005745 ethoxymethyl group Chemical group [H]C([H])([H])C([H])([H])OC([H])([H])* 0.000 description 1
- OPVLYNGAOLVSGF-UHFFFAOYSA-N ethyl 1-(2-chlorophenyl)-4-methyl-[1,2,4]triazolo[4,3-a]quinoxaline-7-carboxylate Chemical compound C=1C(C(=O)OCC)=CC=C(N23)C=1N=C(C)C3=NN=C2C1=CC=CC=C1Cl OPVLYNGAOLVSGF-UHFFFAOYSA-N 0.000 description 1
- MKNKYIBULNNKQR-UHFFFAOYSA-N ethyl 1-(2-chlorophenyl)-4-methyl-[1,2,4]triazolo[4,3-a]quinoxaline-8-carboxylate Chemical compound N12C3=CC(C(=O)OCC)=CC=C3N=C(C)C2=NN=C1C1=CC=CC=C1Cl MKNKYIBULNNKQR-UHFFFAOYSA-N 0.000 description 1
- SKEZDIOVBYJCOV-UHFFFAOYSA-N ethyl 4-methyl-1-phenyl-[1,2,4]triazolo[4,3-a]quinoxaline-7-carboxylate Chemical compound C=1C(C(=O)OCC)=CC=C(N23)C=1N=C(C)C3=NN=C2C1=CC=CC=C1 SKEZDIOVBYJCOV-UHFFFAOYSA-N 0.000 description 1
- ZONQUSFKYYYHPU-UHFFFAOYSA-N ethyl 4-methyl-1-phenyl-[1,2,4]triazolo[4,3-a]quinoxaline-8-carboxylate Chemical compound N12C3=CC(C(=O)OCC)=CC=C3N=C(C)C2=NN=C1C1=CC=CC=C1 ZONQUSFKYYYHPU-UHFFFAOYSA-N 0.000 description 1
- FADBOWPXIRFCGQ-UHFFFAOYSA-N n-[1-(2-chlorophenyl)-4-methyl-[1,2,4]triazolo[4,3-a]quinoxalin-8-yl]propanamide Chemical compound N12C3=CC(NC(=O)CC)=CC=C3N=C(C)C2=NN=C1C1=CC=CC=C1Cl FADBOWPXIRFCGQ-UHFFFAOYSA-N 0.000 description 1
- BNCPRKFNMWSBJU-UHFFFAOYSA-N n-[[1-(2-chloro-5-ethoxyphenyl)-4-methyl-[1,2,4]triazolo[4,3-a]quinoxalin-8-yl]methyl]ethanamine Chemical compound N12C3=CC(CNCC)=CC=C3N=C(C)C2=NN=C1C1=CC(OCC)=CC=C1Cl BNCPRKFNMWSBJU-UHFFFAOYSA-N 0.000 description 1
- XIHPNKLIMDMEDL-UHFFFAOYSA-N n-[[1-(2-chloro-5-ethoxyphenyl)-4-methyl-[1,2,4]triazolo[4,3-a]quinoxalin-8-yl]methyl]pyridin-3-amine Chemical compound CCOC1=CC=C(Cl)C(C=2N3C4=CC(CNC=5C=NC=CC=5)=CC=C4N=C(C)C3=NN=2)=C1 XIHPNKLIMDMEDL-UHFFFAOYSA-N 0.000 description 1
- PKCYMHQCHPYQET-UHFFFAOYSA-N n-[[1-(2-chloro-5-propan-2-yloxyphenyl)-4-methyl-[1,2,4]triazolo[4,3-a]quinoxalin-8-yl]methyl]ethanamine Chemical compound N12C3=CC(CNCC)=CC=C3N=C(C)C2=NN=C1C1=CC(OC(C)C)=CC=C1Cl PKCYMHQCHPYQET-UHFFFAOYSA-N 0.000 description 1
- HWOZZQIWEJEHTR-UHFFFAOYSA-N n-[[1-(2-chloro-5-propan-2-yloxyphenyl)-4-methyl-[1,2,4]triazolo[4,3-a]quinoxalin-8-yl]methyl]pyridin-3-amine Chemical compound CC(C)OC1=CC=C(Cl)C(C=2N3C4=CC(CNC=5C=NC=CC=5)=CC=C4N=C(C)C3=NN=2)=C1 HWOZZQIWEJEHTR-UHFFFAOYSA-N 0.000 description 1
- MSHIPDFLJNFAJC-UHFFFAOYSA-N n-[[1-(2-chloro-5-propoxyphenyl)-4-methyl-[1,2,4]triazolo[4,3-a]quinoxalin-8-yl]methyl]ethanamine Chemical compound CCCOC1=CC=C(Cl)C(C=2N3C4=CC(CNCC)=CC=C4N=C(C)C3=NN=2)=C1 MSHIPDFLJNFAJC-UHFFFAOYSA-N 0.000 description 1
- ACJRYUPFLOVTGF-UHFFFAOYSA-N n-[[1-(2-chloro-5-propoxyphenyl)-4-methyl-[1,2,4]triazolo[4,3-a]quinoxalin-8-yl]methyl]pyridin-3-amine Chemical compound CCCOC1=CC=C(Cl)C(C=2N3C4=CC(CNC=5C=NC=CC=5)=CC=C4N=C(C)C3=NN=2)=C1 ACJRYUPFLOVTGF-UHFFFAOYSA-N 0.000 description 1
- LSOKSPALIMSVDM-UHFFFAOYSA-N n-[[1-(2-chlorophenyl)-4-methyl-[1,2,4]triazolo[4,3-a]quinoxalin-8-yl]methyl]-1-phenylmethanamine Chemical compound C1=C2N3C(C=4C(=CC=CC=4)Cl)=NN=C3C(C)=NC2=CC=C1CNCC1=CC=CC=C1 LSOKSPALIMSVDM-UHFFFAOYSA-N 0.000 description 1
- PMOYHZUHMRBKJN-UHFFFAOYSA-N n-[[1-(2-chlorophenyl)-4-methyl-[1,2,4]triazolo[4,3-a]quinoxalin-8-yl]methyl]ethanamine Chemical compound N12C3=CC(CNCC)=CC=C3N=C(C)C2=NN=C1C1=CC=CC=C1Cl PMOYHZUHMRBKJN-UHFFFAOYSA-N 0.000 description 1
- CHAYLLQTRFSAHL-UHFFFAOYSA-N n-[[1-(2-chlorophenyl)-4-methyl-[1,2,4]triazolo[4,3-a]quinoxalin-8-yl]methyl]oxan-4-amine Chemical compound C1=C2N3C(C=4C(=CC=CC=4)Cl)=NN=C3C(C)=NC2=CC=C1CNC1CCOCC1 CHAYLLQTRFSAHL-UHFFFAOYSA-N 0.000 description 1
- LQRKBCYOWUQCSE-UHFFFAOYSA-N n-[[1-(2-chlorophenyl)-4-methyl-[1,2,4]triazolo[4,3-a]quinoxalin-8-yl]methyl]pyridin-3-amine Chemical compound C1=C2N3C(C=4C(=CC=CC=4)Cl)=NN=C3C(C)=NC2=CC=C1CNC1=CC=CN=C1 LQRKBCYOWUQCSE-UHFFFAOYSA-N 0.000 description 1
- JMURPYMURQWSTJ-UHFFFAOYSA-N n-[[1-(5-butoxy-2-chlorophenyl)-4-methyl-[1,2,4]triazolo[4,3-a]quinoxalin-8-yl]methyl]-1-cyclopropylmethanamine Chemical compound CCCCOC1=CC=C(Cl)C(C=2N3C4=CC(CNCC5CC5)=CC=C4N=C(C)C3=NN=2)=C1 JMURPYMURQWSTJ-UHFFFAOYSA-N 0.000 description 1
- IYVNUVREPJDLRM-UHFFFAOYSA-N n-[[1-(5-butoxy-2-chlorophenyl)-4-methyl-[1,2,4]triazolo[4,3-a]quinoxalin-8-yl]methyl]cyclobutanamine Chemical compound CCCCOC1=CC=C(Cl)C(C=2N3C4=CC(CNC5CCC5)=CC=C4N=C(C)C3=NN=2)=C1 IYVNUVREPJDLRM-UHFFFAOYSA-N 0.000 description 1
- PIRQUJQMIKOECS-UHFFFAOYSA-N n-[[1-(5-butoxy-2-chlorophenyl)-4-methyl-[1,2,4]triazolo[4,3-a]quinoxalin-8-yl]methyl]ethanamine Chemical compound CCCCOC1=CC=C(Cl)C(C=2N3C4=CC(CNCC)=CC=C4N=C(C)C3=NN=2)=C1 PIRQUJQMIKOECS-UHFFFAOYSA-N 0.000 description 1
- RIDZVINUIPDLCQ-UHFFFAOYSA-N n-[[1-(5-butoxy-2-chlorophenyl)-4-methyl-[1,2,4]triazolo[4,3-a]quinoxalin-8-yl]methyl]propan-2-amine Chemical compound CCCCOC1=CC=C(Cl)C(C=2N3C4=CC(CNC(C)C)=CC=C4N=C(C)C3=NN=2)=C1 RIDZVINUIPDLCQ-UHFFFAOYSA-N 0.000 description 1
- JZNVXTPUTSWDLQ-UHFFFAOYSA-N n-[[1-(5-butoxypyridin-3-yl)-4-methyl-[1,2,4]triazolo[4,3-a]quinoxalin-8-yl]methyl]-1-cyclopropylmethanamine Chemical compound CCCCOC1=CN=CC(C=2N3C4=CC(CNCC5CC5)=CC=C4N=C(C)C3=NN=2)=C1 JZNVXTPUTSWDLQ-UHFFFAOYSA-N 0.000 description 1
- PWZRSAKOCVVTET-UHFFFAOYSA-N n-[[1-(5-butoxypyridin-3-yl)-4-methyl-[1,2,4]triazolo[4,3-a]quinoxalin-8-yl]methyl]cyclobutanamine Chemical compound CCCCOC1=CN=CC(C=2N3C4=CC(CNC5CCC5)=CC=C4N=C(C)C3=NN=2)=C1 PWZRSAKOCVVTET-UHFFFAOYSA-N 0.000 description 1
- XKVJQGZBJHTMTI-UHFFFAOYSA-N n-[[1-(5-butoxypyridin-3-yl)-4-methyl-[1,2,4]triazolo[4,3-a]quinoxalin-8-yl]methyl]ethanamine Chemical compound CCCCOC1=CN=CC(C=2N3C4=CC(CNCC)=CC=C4N=C(C)C3=NN=2)=C1 XKVJQGZBJHTMTI-UHFFFAOYSA-N 0.000 description 1
- BHMXFSJSWADVLS-UHFFFAOYSA-N n-[[1-(5-butoxypyridin-3-yl)-4-methyl-[1,2,4]triazolo[4,3-a]quinoxalin-8-yl]methyl]propan-2-amine Chemical compound CCCCOC1=CN=CC(C=2N3C4=CC(CNC(C)C)=CC=C4N=C(C)C3=NN=2)=C1 BHMXFSJSWADVLS-UHFFFAOYSA-N 0.000 description 1
- CXUDCXWYUYKHFN-UHFFFAOYSA-N n-[[1-[5-(cyclopropylmethoxy)pyridin-3-yl]-4-methyl-[1,2,4]triazolo[4,3-a]quinoxalin-8-yl]methyl]cyclobutanamine Chemical compound C1=C2N3C(C=4C=C(OCC5CC5)C=NC=4)=NN=C3C(C)=NC2=CC=C1CNC1CCC1 CXUDCXWYUYKHFN-UHFFFAOYSA-N 0.000 description 1
- ZHOGIIGEXYVVFK-UHFFFAOYSA-N n-[[1-[5-(cyclopropylmethoxy)pyridin-3-yl]-4-methyl-[1,2,4]triazolo[4,3-a]quinoxalin-8-yl]methyl]ethanamine Chemical compound N12C3=CC(CNCC)=CC=C3N=C(C)C2=NN=C1C(C=1)=CN=CC=1OCC1CC1 ZHOGIIGEXYVVFK-UHFFFAOYSA-N 0.000 description 1
- PVSWNXAQGIZVRS-UHFFFAOYSA-N n-[[1-[5-(ethoxymethyl)pyridin-3-yl]-4-methyl-[1,2,4]triazolo[4,3-a]quinoxalin-8-yl]methyl]cyclobutanamine Chemical compound CCOCC1=CN=CC(C=2N3C4=CC(CNC5CCC5)=CC=C4N=C(C)C3=NN=2)=C1 PVSWNXAQGIZVRS-UHFFFAOYSA-N 0.000 description 1
- OMJDTJPGMCDEOB-UHFFFAOYSA-N n-[[4-methyl-1-(5-propoxypyridin-3-yl)-[1,2,4]triazolo[4,3-a]quinoxalin-8-yl]methyl]cyclobutanamine Chemical compound CCCOC1=CN=CC(C=2N3C4=CC(CNC5CCC5)=CC=C4N=C(C)C3=NN=2)=C1 OMJDTJPGMCDEOB-UHFFFAOYSA-N 0.000 description 1
- YGNSXEDMBFIFRU-UHFFFAOYSA-N n-[[4-methyl-1-(5-propoxypyridin-3-yl)-[1,2,4]triazolo[4,3-a]quinoxalin-8-yl]methyl]ethanamine Chemical compound CCCOC1=CN=CC(C=2N3C4=CC(CNCC)=CC=C4N=C(C)C3=NN=2)=C1 YGNSXEDMBFIFRU-UHFFFAOYSA-N 0.000 description 1
- LPZCANRRYYLKAQ-UHFFFAOYSA-N n-benzyl-1-(2-chlorophenyl)-4-methyl-[1,2,4]triazolo[4,3-a]quinoxaline-8-carboxamide Chemical compound N=1N=C2C(C)=NC3=CC=C(C(=O)NCC=4C=CC=CC=4)C=C3N2C=1C1=CC=CC=C1Cl LPZCANRRYYLKAQ-UHFFFAOYSA-N 0.000 description 1
- BNPYRPMSUNIRRJ-UHFFFAOYSA-N n-benzyl-4-methyl-1-phenyl-[1,2,4]triazolo[4,3-a]quinoxaline-7-carboxamide Chemical compound N=1N=C2C(C)=NC3=CC(C(=O)NCC=4C=CC=CC=4)=CC=C3N2C=1C1=CC=CC=C1 BNPYRPMSUNIRRJ-UHFFFAOYSA-N 0.000 description 1
- HIUJNBXYERGONS-UHFFFAOYSA-N n-benzyl-4-methyl-1-phenyl-[1,2,4]triazolo[4,3-a]quinoxaline-8-carboxamide Chemical compound N=1N=C2C(C)=NC3=CC=C(C(=O)NCC=4C=CC=CC=4)C=C3N2C=1C1=CC=CC=C1 HIUJNBXYERGONS-UHFFFAOYSA-N 0.000 description 1
- LQSCREXWTVUPGQ-UHFFFAOYSA-N n-benzyl-n,4-dimethyl-1-phenyl-[1,2,4]triazolo[4,3-a]quinoxaline-8-carboxamide Chemical compound C=1C=C2N=C(C)C3=NN=C(C=4C=CC=CC=4)N3C2=CC=1C(=O)N(C)CC1=CC=CC=C1 LQSCREXWTVUPGQ-UHFFFAOYSA-N 0.000 description 1
- ASJRPPJEYHNNET-UHFFFAOYSA-N n-ethyl-1-(2-fluorophenyl)-4-methyl-[1,2,4]triazolo[4,3-a]quinoxaline-8-carboxamide Chemical compound N12C3=CC(C(=O)NCC)=CC=C3N=C(C)C2=NN=C1C1=CC=CC=C1F ASJRPPJEYHNNET-UHFFFAOYSA-N 0.000 description 1
- HXWSGMZHUJKHOE-UHFFFAOYSA-N n-ethyl-1-(2-methoxyphenyl)-4-methyl-[1,2,4]triazolo[4,3-a]quinoxaline-8-carboxamide Chemical compound N12C3=CC(C(=O)NCC)=CC=C3N=C(C)C2=NN=C1C1=CC=CC=C1OC HXWSGMZHUJKHOE-UHFFFAOYSA-N 0.000 description 1
- FEDOZVCITUGSNH-UHFFFAOYSA-N n-ethyl-1-(2-methoxypyridin-3-yl)-4-methyl-[1,2,4]triazolo[4,3-a]quinoxaline-7-carboxamide Chemical compound C=1C(C(=O)NCC)=CC=C(N23)C=1N=C(C)C3=NN=C2C1=CC=CN=C1OC FEDOZVCITUGSNH-UHFFFAOYSA-N 0.000 description 1
- QVUMIQCLVPRUBJ-UHFFFAOYSA-N n-ethyl-1-(2-methoxypyridin-3-yl)-4-methyl-[1,2,4]triazolo[4,3-a]quinoxaline-8-carboxamide Chemical compound N12C3=CC(C(=O)NCC)=CC=C3N=C(C)C2=NN=C1C1=CC=CN=C1OC QVUMIQCLVPRUBJ-UHFFFAOYSA-N 0.000 description 1
- NFLIWCYWMWIGMV-UHFFFAOYSA-N n-ethyl-1-(5-methoxypyridin-3-yl)-4-methyl-[1,2,4]triazolo[4,3-a]quinoxaline-7-carboxamide Chemical compound C=1C(C(=O)NCC)=CC=C(N23)C=1N=C(C)C3=NN=C2C1=CN=CC(OC)=C1 NFLIWCYWMWIGMV-UHFFFAOYSA-N 0.000 description 1
- UMJOYABDDYRKPH-UHFFFAOYSA-N n-ethyl-1-(5-methoxypyridin-3-yl)-4-methyl-[1,2,4]triazolo[4,3-a]quinoxaline-8-carboxamide Chemical compound N12C3=CC(C(=O)NCC)=CC=C3N=C(C)C2=NN=C1C1=CN=CC(OC)=C1 UMJOYABDDYRKPH-UHFFFAOYSA-N 0.000 description 1
- NZDZJCZDEDCEHQ-UHFFFAOYSA-N n-ethyl-4-methyl-1-(2-methylpyridin-3-yl)-[1,2,4]triazolo[4,3-a]quinoxaline-7-carboxamide Chemical compound C=1C(C(=O)NCC)=CC=C(N23)C=1N=C(C)C3=NN=C2C1=CC=CN=C1C NZDZJCZDEDCEHQ-UHFFFAOYSA-N 0.000 description 1
- GXLBTPXQMQEFQS-UHFFFAOYSA-N n-ethyl-4-methyl-1-(2-methylpyridin-3-yl)-[1,2,4]triazolo[4,3-a]quinoxaline-8-carboxamide Chemical compound N12C3=CC(C(=O)NCC)=CC=C3N=C(C)C2=NN=C1C1=CC=CN=C1C GXLBTPXQMQEFQS-UHFFFAOYSA-N 0.000 description 1
- MDTQFZDLEZMOSM-UHFFFAOYSA-N n-ethyl-4-methyl-1-(4-methylpyridin-3-yl)-[1,2,4]triazolo[4,3-a]quinoxaline-8-carboxamide Chemical compound N12C3=CC(C(=O)NCC)=CC=C3N=C(C)C2=NN=C1C1=CN=CC=C1C MDTQFZDLEZMOSM-UHFFFAOYSA-N 0.000 description 1
- PNBCGXHQDAXONB-UHFFFAOYSA-N n-ethyl-4-methyl-1-(6-methylpyridin-3-yl)-[1,2,4]triazolo[4,3-a]quinoxaline-8-carboxamide Chemical compound N12C3=CC(C(=O)NCC)=CC=C3N=C(C)C2=NN=C1C1=CC=C(C)N=C1 PNBCGXHQDAXONB-UHFFFAOYSA-N 0.000 description 1
- ZQOHAFYHYPKHNN-UHFFFAOYSA-N n-ethyl-4-methyl-1-phenyl-[1,2,4]triazolo[4,3-a]quinoxaline-8-carboxamide Chemical compound N12C3=CC(C(=O)NCC)=CC=C3N=C(C)C2=NN=C1C1=CC=CC=C1 ZQOHAFYHYPKHNN-UHFFFAOYSA-N 0.000 description 1
- CBPBGAAUJILPTQ-UHFFFAOYSA-N n-ethyl-4-methyl-1-pyridin-2-yl-[1,2,4]triazolo[4,3-a]quinoxaline-8-carboxamide Chemical compound N12C3=CC(C(=O)NCC)=CC=C3N=C(C)C2=NN=C1C1=CC=CC=N1 CBPBGAAUJILPTQ-UHFFFAOYSA-N 0.000 description 1
- DBZJUMHACWPWRD-UHFFFAOYSA-N n-ethyl-4-methyl-1-pyridin-3-yl-[1,2,4]triazolo[4,3-a]quinoxaline-8-carboxamide Chemical compound N12C3=CC(C(=O)NCC)=CC=C3N=C(C)C2=NN=C1C1=CC=CN=C1 DBZJUMHACWPWRD-UHFFFAOYSA-N 0.000 description 1
- LUPWGSHPWCTGJI-UHFFFAOYSA-N n-ethyl-4-methyl-1-pyridin-4-yl-[1,2,4]triazolo[4,3-a]quinoxaline-8-carboxamide Chemical compound N12C3=CC(C(=O)NCC)=CC=C3N=C(C)C2=NN=C1C1=CC=NC=C1 LUPWGSHPWCTGJI-UHFFFAOYSA-N 0.000 description 1
- 239000012453 solvate Substances 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP11171519 | 2011-06-27 | ||
| EP11171519.9 | 2011-06-27 | ||
| PCT/EP2012/062381 WO2013000924A1 (en) | 2011-06-27 | 2012-06-26 | 1-ARYL-4-METHYL-[1,2,4]TRIAZOLO[4,3-a]QUINOXALINE DERIVATIVES |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2014518234A JP2014518234A (ja) | 2014-07-28 |
| JP2014518234A5 true JP2014518234A5 (enExample) | 2016-09-08 |
| JP6115962B2 JP6115962B2 (ja) | 2017-04-19 |
Family
ID=44370665
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014517667A Expired - Fee Related JP6115962B2 (ja) | 2011-06-27 | 2012-06-26 | １−アリール−４−メチル−［１，２，４］トリアゾロ［４，３−ａ］キノキサリン誘導体 |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US10604523B2 (enExample) |
| EP (1) | EP2723744B1 (enExample) |
| JP (1) | JP6115962B2 (enExample) |
| CN (1) | CN103619846B (enExample) |
| AU (1) | AU2012277912B2 (enExample) |
| BR (1) | BR112013033375B1 (enExample) |
| CA (1) | CA2838645C (enExample) |
| EA (1) | EA027418B1 (enExample) |
| ES (1) | ES2575092T3 (enExample) |
| MX (1) | MX344600B (enExample) |
| WO (1) | WO2013000924A1 (enExample) |
Families Citing this family (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9540379B2 (en) | 2011-01-31 | 2017-01-10 | Boehringer Ingelheim International Gmbh | (1,2,4)triazolo[4,3-A]quinoxaline derivatives as inhibitors of phosphodiesterases |
| ES2575092T3 (es) | 2011-06-27 | 2016-06-24 | Janssen Pharmaceutica, N.V. | Derivados de 1-aril-4-metil-[1,2,4]triazolo[4,3-a]quinoxalina |
| EP2763989A1 (en) * | 2011-09-09 | 2014-08-13 | H. Lundbeck A/S | Pyridine compounds and uses thereof |
| RU2657540C2 (ru) * | 2012-06-26 | 2018-06-14 | Янссен Фармацевтика Нв | Комбинации, содержащие ингибиторы pde 2, такие как 1-арил-4-метил-[1,2,4]триазоло[4,3-а]хиноксалиновые соединения, и ингибиторы pde 10, для применения в лечении неврологических или метаболических расстройств |
| US20140045856A1 (en) | 2012-07-31 | 2014-02-13 | Boehringer Ingelheim International Gmbh | 4-Methyl-2,3,5,9,9b-pentaaza-cyclopenta[a]naphthalenes |
| CA2899781A1 (en) * | 2013-01-31 | 2014-08-07 | F.Hoffmann-La Roche Ag | Radiolabeled compounds |
| WO2014139983A1 (en) | 2013-03-13 | 2014-09-18 | H. Lundbeck A/S | [1,2,4]triazolo[4,3-a]quinoxalines as dual pde2/pde10 inhibitors |
| EP3091983B1 (en) | 2014-01-08 | 2019-10-02 | Intra-Cellular Therapies, Inc. | Pharmaceutical compositions comprising a pde-1 inhibitor and a pde-2 inhibitor |
| HRP20212035T1 (hr) | 2014-04-23 | 2022-04-01 | Dart Neuroscience Llc | Pripravci koji sadrže supstituirane [1,2,4]triazolo[1,5-a]pirimidin-7-il spojeve kao inhibitore pde2 |
| TWI568737B (zh) | 2014-11-05 | 2017-02-01 | 達特神經科學（開曼）有限責任公司 | 作為ｐｄｅ２抑制劑之經取代的５－甲基－［１，２，４］三唑并［１，５－ａ］嘧啶－２－胺化合物 |
| AU2015357498B2 (en) | 2014-12-06 | 2019-09-12 | Intra-Cellular Therapies, Inc. | Organic compounds |
| MX371158B (es) | 2014-12-06 | 2020-01-20 | Intra Cellular Therapies Inc | Compuestos inhibidores de pde2. |
| WO2016145614A1 (en) | 2015-03-17 | 2016-09-22 | Merck Sharp & Dohme Corp. | Triazolyl pyrimidinone compounds as pde2 inhibitors |
| US10287269B2 (en) | 2015-03-26 | 2019-05-14 | Merck Sharp & Dohme Corp. | Pyrazolyl pyrimidinone compounds as PDE2 inhibitors |
| WO2016179059A1 (en) | 2015-05-05 | 2016-11-10 | Merck Sharp & Dohme Corp. | Heteroaryl-pyrimidinone compounds as pde2 inhibitors |
| WO2016183741A1 (en) | 2015-05-15 | 2016-11-24 | Merck Sharp & Dohme Corp. | Pyrimidinone amide compounds as pde2 inhibitors |
| WO2016191935A1 (en) | 2015-05-29 | 2016-12-08 | Merck Sharp & Dohme Corp. | 6-alkyl dihydropyrazolopyrimidinone compounds as pde2 inhibitors |
| WO2016192083A1 (en) * | 2015-06-04 | 2016-12-08 | Merck Sharp & Dohme Corp. | Dihydropyrazolopyrimidinone compounds as pde2 inhibitors |
| WO2016209749A1 (en) | 2015-06-25 | 2016-12-29 | Merck Sharp & Dohme Corp. | Substituted pyrazolo/imidazolo bicyclic compounds as pde2 inhibitors |
| WO2017000277A1 (en) | 2015-07-01 | 2017-01-05 | Merck Sharp & Dohme Corp. | Substituted triazolo bicycliccompounds as pde2 inhibitors |
| WO2017000276A1 (en) | 2015-07-01 | 2017-01-05 | Merck Sharp & Dohme Corp. | Bicyclic heterocyclic compounds as pde2 inhibitors |
| EP3156405A1 (en) | 2015-10-13 | 2017-04-19 | Boehringer Ingelheim International GmbH | Spirocyclic ether derivatives of pyrazolo[1,5-a]pyrimidine-3-carboxamide |
| MX2018005342A (es) | 2015-11-02 | 2018-08-15 | Janseen Pharmaceutica Nv | Compuesto de [1,2,4]triazolo[1,5-a]pirimidin-7-ilo. |
| EP3440071A1 (en) | 2016-03-21 | 2019-02-13 | Perlara PBC | Fused heterocyclic organic compounds and uses thereof |
| ES2912264T3 (es) | 2016-11-02 | 2022-05-25 | Janssen Pharmaceutica Nv | Compuestos de [1,2,4]triazolo[1,5-a]pirimidina como inhibidores de PDE2 |
| SG11201903892UA (en) | 2016-11-02 | 2019-05-30 | Janssen Pharmaceutica Nv | [1,2,4]triazolo[1,5-a]pyrimidine derivatives as pde2 inhibitors |
| BR112019008163A2 (pt) * | 2016-11-02 | 2019-07-09 | Janssen Pharmaceutica Nv | compostos de [1,2,4]triazolo[1,5-a]pirimidina como inibidores de pde2 |
| CN107827828B (zh) * | 2017-11-21 | 2021-03-30 | 南京华漫新材料科技有限公司 | 含苯酰肼骨架的喹喔啉衍生物及其制备方法和在制备抗肿瘤药物中的应用 |
| JP2021504466A (ja) | 2017-11-23 | 2021-02-15 | オスロ ウニヴェルシティ ホスピタル ホーエフ | 頻脈の治療 |
Family Cites Families (214)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS5584421A (en) | 1978-12-21 | 1980-06-25 | Mitsui Cokes Kogyo Kk | Method of making fibrous carbon |
| US4242513A (en) | 1979-03-05 | 1980-12-30 | Appleton Papers Inc. | Lactone compounds containing a heterocyclic radical |
| EP0226641B1 (en) | 1985-05-25 | 1989-10-18 | Yoshitomi Pharmaceutical Industries, Ltd. | Oxodiazine compounds |
| WO1991000092A1 (en) | 1989-06-13 | 1991-01-10 | Smithkline Beecham Corporation | Inhibition of interleukin-1 and tumor necrosis factor production by monocytes and/or macrophages |
| WO1990015534A1 (en) | 1989-06-13 | 1990-12-27 | Smithkline Beecham Corporation | Monokine activity interference |
| AU622330B2 (en) | 1989-06-23 | 1992-04-02 | Takeda Chemical Industries Ltd. | Condensed heterocyclic compounds having a nitrogen atom in the bridgehead for use as fungicides |
| KR910011852A (ko) | 1989-12-04 | 1991-08-07 | 폴 디. 매튜카이티스 | 신경독 장해 치료용 이미다조[1,2-a]피리디닐알킬 화합물 |
| CA2084290A1 (en) | 1990-06-12 | 1991-12-13 | Jerry L. Adams | Inhibition of 5-lipoxygenase and cyclooxygenase pathway mediated diseases |
| US5137876A (en) | 1990-10-12 | 1992-08-11 | Merck & Co., Inc. | Nucleoside antiviral and anti-inflammatory compounds and compositions and methods for using same |
| JPH06504779A (ja) | 1990-12-13 | 1994-06-02 | スミスクライン・ビーチャム・コーポレイション | 新規ｃｓａｉｄｓ |
| AU9169991A (en) | 1990-12-13 | 1992-07-08 | Smithkline Beecham Corporation | Novel csaids |
| US5683998A (en) | 1991-04-23 | 1997-11-04 | Toray Industries, Inc. | Tricyclic triazolo derivatives, processes for producing the same and the uses of the same |
| CN1033327C (zh) * | 1991-04-23 | 1996-11-20 | 东丽株式会社 | 三环三唑并衍生物的制造方法 |
| DK31093D0 (enExample) | 1993-03-19 | 1993-03-19 | Novo Nordisk As | |
| US5486525A (en) | 1993-12-16 | 1996-01-23 | Abbott Laboratories | Platelet activating factor antagonists: imidazopyridine indoles |
| US5869486A (en) | 1995-02-24 | 1999-02-09 | Ono Pharmaceutical Co., Ltd. | Fused pyrimidines and pyriazines as pharmaceutical compounds |
| JPH11505524A (ja) | 1995-05-01 | 1999-05-21 | 藤沢薬品工業株式会社 | イミダゾ１，２−ａピリジンおよびイミダゾ１，２−ａピリデジン誘導体、および骨吸収阻害剤としてのその用途 |
| US6992188B1 (en) | 1995-12-08 | 2006-01-31 | Pfizer, Inc. | Substituted heterocyclic derivatives |
| US20010007867A1 (en) | 1999-12-13 | 2001-07-12 | Yuhpyng L. Chen | Substituted 6,5-hetero-bicyclic derivatives |
| WO1998035967A2 (en) | 1997-02-18 | 1998-08-20 | Neurocrine Biosciences, Inc. | Biazacyclic crf antagonists |
| WO1998039342A1 (en) | 1997-03-07 | 1998-09-11 | Metabasis Therapeutics, Inc. | Novel indole and azaindole inhibitors of fructose-1,6-bisphosphatase |
| IL134748A0 (en) | 1997-09-02 | 2001-04-30 | Du Pont Pharm Co | Heterocyclyl-substituted ring-fused pyridines and pyrimidines as corticotropin releasing hormone (crh) antagonists, useful for treating cns and stress-related disorders |
| WO2000001376A2 (en) | 1998-07-02 | 2000-01-13 | Eisai Co., Ltd | Pharmaceutical compositions and their uses for treatment of demyelinating disorders |
| US6248755B1 (en) | 1999-04-06 | 2001-06-19 | Merck & Co., Inc. | Pyrrolidine modulators of chemokine receptor activity |
| JP4032566B2 (ja) | 1999-06-21 | 2008-01-16 | 東レ株式会社 | 発光素子 |
| JP2001057292A (ja) | 1999-08-20 | 2001-02-27 | Toray Ind Inc | 発光素子 |
| GB9919778D0 (en) | 1999-08-21 | 1999-10-27 | Zeneca Ltd | Chemical compounds |
| CO5271670A1 (es) | 1999-10-29 | 2003-04-30 | Pfizer Prod Inc | Antagonistas del factor de liberacion de corticitropina y composiciones relacionadas |
| EP1293213A1 (en) | 2000-02-14 | 2003-03-19 | Japan Tobacco Inc. | Preventives/remedies for postoperative stress |
| EP1149583A3 (en) | 2000-04-13 | 2001-11-14 | Pfizer Products Inc. | Combinations of corticotropin releasing factor antagonists and growth hormone secretagogues |
| US6403588B1 (en) | 2000-04-27 | 2002-06-11 | Yamanouchi Pharmaceutical Co., Ltd. | Imidazopyridine derivatives |
| CA2419626A1 (en) | 2000-07-14 | 2002-01-24 | Rajagopal Bakthavatachalam | Imidazo¬1,2-a|pyrazines for the treatment of neurological disorders |
| WO2002034748A1 (fr) | 2000-10-24 | 2002-05-02 | Sankyo Company, Limited | Derives d'imidazopyridine |
| EP1343785A2 (de) | 2000-12-13 | 2003-09-17 | Basf Aktiengesellschaft | Verwendung von substituierten imidazoazinen, neue imidazoazine, verfahren zu deren herstellung, sowie sie enthaltende mittel |
| SK286630B6 (sk) | 2001-01-22 | 2009-02-05 | Merck & Co., Inc. | Nukleozidové deriváty, farmaceutický prostriedok s ich obsahom a ich použitie |
| TWI312347B (en) | 2001-02-08 | 2009-07-21 | Eisai R&D Man Co Ltd | Bicyclic nitrogen-containing condensed ring compounds |
| GB0103926D0 (en) | 2001-02-17 | 2001-04-04 | Astrazeneca Ab | Chemical compounds |
| CN100415744C (zh) | 2001-02-20 | 2008-09-03 | 阿斯特拉曾尼卡有限公司 | 用于治疗与gsk3有关的病症的2-芳基氨基-嘧啶 |
| SE0100568D0 (sv) | 2001-02-20 | 2001-02-20 | Astrazeneca Ab | Compounds |
| EP1373240B1 (en) | 2001-03-14 | 2005-06-15 | Eli Lilly And Company | Retinoid x receptor modulators |
| WO2002088107A1 (fr) | 2001-04-26 | 2002-11-07 | Eisai Co., Ltd. | Compose azote a anneaux condenses possedant un groupe pyrazolyle et servant de substituant, et composition medicale le comprenant |
| US6806268B2 (en) | 2001-05-30 | 2004-10-19 | Alteon, Inc. | Method for treating glaucoma V |
| WO2002096363A2 (en) | 2001-05-30 | 2002-12-05 | Alteon, Inc. | Method for treating fibrotic diseases or other indications |
| JP2005500315A (ja) | 2001-06-21 | 2005-01-06 | スミスクライン ビーチャム コーポレーション | ヘルペスウイルス感染の予防および治療用イミダゾ［１，２−ａ］ピリジン誘導体 |
| CA2450555A1 (en) | 2001-06-25 | 2003-01-03 | Merck & Co., Inc. | (pyrimidyl)(phenyl)substituted fused heteroaryl p38 inhibiting and pkg kinase inhibiting compounds |
| IL159811A0 (en) | 2001-07-13 | 2004-06-20 | Neurogen Corp | Heteroaryl substituted fused bicyclic heteroaryl compounds as gabaa receptor ligands |
| JP2005508955A (ja) | 2001-10-05 | 2005-04-07 | スミスクライン ビーチャム コーポレーション | ヘルペスウイルス感染の治療で使用されるためのイミダゾ−ピリジン誘導体 |
| EP1469849A4 (en) | 2002-01-22 | 2007-06-27 | Merck & Co Inc | TREATMENT OF STRESS REACTIONS WITH CHEMOKIN RECEPTOR CCR5 MODULATORS |
| CN1312154C (zh) | 2002-03-05 | 2007-04-25 | 伊莱利利公司 | 作为激酶抑制剂的嘌呤衍生物 |
| JP2003313126A (ja) | 2002-04-23 | 2003-11-06 | Sankyo Co Ltd | イミダゾピリジン誘導体を有効成分とする医薬 |
| JP2004002826A (ja) | 2002-04-24 | 2004-01-08 | Sankyo Co Ltd | 高分子イミダゾピリジン誘導体 |
| EP1505979A4 (en) | 2002-05-13 | 2006-08-30 | Merck & Co Inc | PHENYL-SUBSTITUTED IMIDAZOPYRIDINES AND PHENYL-SUBSTITUTED BENZIMIDAZOLE |
| WO2003099840A1 (en) | 2002-05-24 | 2003-12-04 | Isis Pharmaceuticals, Inc. | Oligonucleotides having modified nucleoside units |
| GB0217783D0 (en) | 2002-07-31 | 2002-09-11 | Glaxo Group Ltd | Compounds |
| AU2003260345A1 (en) | 2002-07-31 | 2004-02-23 | Smithkline Beecham Corporation | 2-phenylpyridin-4-yl derivatives as alk5 inhibitors |
| DE60309342T2 (de) | 2002-08-09 | 2007-05-16 | Eli Lilly And Co., Indianapolis | Benzimidazole und benzothiazole als inhibitoren der map-kinase |
| AU2003255845A1 (en) | 2002-08-22 | 2004-03-11 | Piramed Limited | Phosphadidylinositol 3,5-biphosphate inhibitors as anti-viral agents |
| UA80296C2 (en) | 2002-09-06 | 2007-09-10 | Biogen Inc | Imidazolopyridines and methods of making and using the same |
| AU2003270489A1 (en) | 2002-09-09 | 2004-03-29 | Cellular Genomics, Inc. | 6-ARYL-IMIDAZO(1,2-a)PYRAZIN-8-YLAMINES, METHOD OF MAKING, AND METHOD OF USE THEREOF |
| AU2003267087A1 (en) | 2002-09-13 | 2004-04-30 | Merck & Co., Inc. | Fused heterobicyclo substituted phenyl metabotropic glutamate-5 modulators |
| EP1539756B1 (en) | 2002-09-19 | 2007-11-14 | Schering Corporation | Imidazopyridines as cyclin dependent kinase inhibitors |
| TW200413378A (en) | 2002-09-23 | 2004-08-01 | Schering Corp | Novel imidazopyrazines as cyclin dependent kinase inhibitors |
| US7576085B2 (en) | 2002-09-23 | 2009-08-18 | Schering Corporation | Imidazopyrazines as cyclin dependent kinase inhibitors |
| WO2004026310A1 (en) | 2002-09-23 | 2004-04-01 | Schering Corporation | Novel imidazopyrazines as cyclin dependent kinase inhibitors |
| WO2004035579A1 (ja) | 2002-10-15 | 2004-04-29 | Takeda Pharmaceutical Company Limited | イミダゾピリジン誘導体、その製造法および用途 |
| WO2004046331A2 (en) | 2002-11-15 | 2004-06-03 | Idenix (Cayman) Limited | 2’-branched nucleosides and flaviviridae mutation |
| EP1564213A4 (en) | 2002-11-22 | 2009-05-27 | Takeda Pharmaceutical | IMIDAZOLE DERIVATIVE, METHOD FOR THE PRODUCTION AND USE THEREOF |
| WO2004063159A1 (ja) | 2003-01-10 | 2004-07-29 | Idemitsu Kosan Co., Ltd. | 含窒素複素環誘導体及びそれを用いた有機エレクトロルミネッセンス素子 |
| WO2004072080A1 (en) | 2003-02-10 | 2004-08-26 | Cellular Genomics, Inc. | Certain 8-heteroaryl-6-phenyl-imidazo[1,2-a]pyrazines as modulators of hsp90 complex activity |
| US7186832B2 (en) | 2003-02-20 | 2007-03-06 | Sugen Inc. | Use of 8-amino-aryl-substituted imidazopyrazines as kinase inhibitors |
| US7329668B2 (en) | 2003-02-25 | 2008-02-12 | Bristol-Myers Squibb Company | Pyrazolopurine-based tricyclic compounds and pharmaceutical compositions comprising same |
| PA8595001A1 (es) | 2003-03-04 | 2004-09-28 | Pfizer Prod Inc | Nuevos compuestos heteroaromaticos condensados que son inhibidores del factor de crecimiento transforante (tgf) |
| US7041671B2 (en) | 2003-04-02 | 2006-05-09 | Pfizer Inc | Pyrrolo[1,2-b]pyridazine compounds and their uses |
| US20060094699A1 (en) | 2003-04-11 | 2006-05-04 | Kampen Gita Camilla T | Combination therapy using an 11beta-hydroxysteroid dehydrogenase type 1 inhibitor and a glucocorticoid receptor agonist to minimize the side effects associated with glucocorticoid receptor agonist therapy |
| US20060100235A1 (en) | 2003-04-11 | 2006-05-11 | Novo Nordisk A/S | Pharmaceutical use of substituted 1,2,4-triazoles |
| JP2006522750A (ja) | 2003-04-11 | 2006-10-05 | ノボ ノルディスク アクティーゼルスカブ | 代謝性症候群ならびに関連の疾患および障害を治療するために、１１β−ヒドロキシステロイドデヒドロゲナーゼ１型阻害剤および抗高血圧剤を使用する併用療法 |
| WO2004103991A1 (en) | 2003-05-20 | 2004-12-02 | 'chemical Diversity Research Institute', Ltd. | 2-substituted piperidines, focused library and a pharmaceutical compound |
| WO2005020885A2 (en) | 2003-05-21 | 2005-03-10 | Isis Pharmaceuticals, Inc. | Compositions and methods for the treatment of severe acute respiratory syndrome (sars) |
| WO2004106276A1 (ja) | 2003-05-30 | 2004-12-09 | Takeda Pharmaceutical Company Limited | 縮合環化合物 |
| US7405295B2 (en) | 2003-06-04 | 2008-07-29 | Cgi Pharmaceuticals, Inc. | Certain imidazo[1,2-a]pyrazin-8-ylamines and method of inhibition of Bruton's tyrosine kinase by such compounds |
| WO2005005429A1 (en) | 2003-06-30 | 2005-01-20 | Cellular Genomics, Inc. | Certain heterocyclic substituted imidazo[1,2-a]pyrazin-8-ylamines and methods of inhibition of bruton’s tyrosine kinase by such compounds |
| EP2287165A3 (en) | 2003-07-14 | 2011-06-22 | Arena Pharmaceuticals, Inc. | Fused-aryl and heteroaryl derivatives as modulators of metabolism and the prophylaxis and treatment of disorders related thereto |
| WO2005019220A2 (en) | 2003-08-11 | 2005-03-03 | Cellular Genomics Inc. | Substituted imidazo[1,2-a]pyrazines as modulators of kinase activity |
| KR100553752B1 (ko) | 2003-10-13 | 2006-02-20 | 삼성에스디아이 주식회사 | 이미다졸 고리 함유 화합물 및 이를 이용한 유기 전계발광 소자 |
| AU2004287847A1 (en) | 2003-10-28 | 2005-05-19 | Sepracor Inc. | Imidazo(1,2-a)pyridine anxiolytics |
| US20050288295A1 (en) | 2003-11-11 | 2005-12-29 | Currie Kevin S | Certain imidazo[1,2-a]pyrazin-8-ylamines, method of making, and method of use thereof |
| EP1713784A1 (en) | 2004-02-12 | 2006-10-25 | Neurogen Corporation | Imidazo-pyridazines, triazolo-pyridazines and related benzodiazepine receptor ligands |
| US7306631B2 (en) | 2004-03-30 | 2007-12-11 | The Procter & Gamble Company | Keratin dyeing compounds, keratin dyeing compositions containing them, and use thereof |
| JP2005343889A (ja) | 2004-05-06 | 2005-12-15 | Taisho Pharmaceut Co Ltd | イミダゾピリジン誘導体 |
| ATE424208T1 (de) | 2004-06-09 | 2009-03-15 | Oncalis Ag | Proteinkinaseinhibitoren |
| GB0413605D0 (en) | 2004-06-17 | 2004-07-21 | Addex Pharmaceuticals Sa | Novel compounds |
| US7718801B2 (en) | 2004-08-31 | 2010-05-18 | Banyu Pharmaceutical Co., Ltd. | Substituted imidazole derivative |
| WO2006044509A2 (en) | 2004-10-15 | 2006-04-27 | Biogen Idec Ma Inc. | Methods of treating vascular injuries |
| CN101083996A (zh) | 2004-10-28 | 2007-12-05 | Irm责任有限公司 | 作为hedgehog途径调节剂的化合物和组合物 |
| WO2006049339A1 (ja) | 2004-11-08 | 2006-05-11 | Banyu Pharmaceutical Co., Ltd. | 新規縮環イミダゾール誘導体 |
| NZ555681A (en) | 2004-11-10 | 2009-08-28 | Cgi Pharmaceuticals Inc | Imidazo[1, 2-a] pyrazin-8-ylamines useful as modulators of kinase activity |
| EP1838312A4 (en) | 2004-12-17 | 2010-01-20 | Smithkline Beecham Corp | CHEMICAL COMPOUNDS |
| US20080167314A1 (en) | 2004-12-28 | 2008-07-10 | Osamu Uchikawa | Condensed Imidazole Compound And Use Thereof |
| EP1853590A1 (en) | 2005-03-03 | 2007-11-14 | Sirtris Pharmaceuticals, Inc. | Fused heterocyclic compounds and their use as sirtuin modulators |
| DK1869049T3 (da) | 2005-03-21 | 2009-05-18 | Lilly Co Eli | Imidazopyridazinforbindelser |
| US7666880B2 (en) | 2005-03-21 | 2010-02-23 | S*Bio Pte Ltd. | Imidazo[1,2-A]pyridine derivatives: preparation and pharmaceutical applications |
| US20080255358A1 (en) | 2005-03-24 | 2008-10-16 | Mark James Bamford | Derivatives of Imidazo [1,2-A] Pyridine Useful as Medicaments For Treating Gastrointestinal Diseases |
| EP1879896A1 (en) | 2005-04-05 | 2008-01-23 | Eli Lilly And Company | Imidazopyridazine compounds |
| US7572807B2 (en) | 2005-06-09 | 2009-08-11 | Bristol-Myers Squibb Company | Heteroaryl 11-beta-hydroxysteroid dehydrogenase type I inhibitors |
| GB0513423D0 (en) | 2005-06-30 | 2005-08-03 | Glaxo Group Ltd | Novel compounds |
| ES2396671T3 (es) | 2005-07-11 | 2013-02-25 | Novartis Ag | Derivados de la indolilmaleimida como inhibidores de la proteína quinasa |
| EP1910369A1 (en) | 2005-07-29 | 2008-04-16 | Astellas Pharma Inc. | Fused heterocycles as lck inhibitors |
| US20070185063A1 (en) | 2005-08-23 | 2007-08-09 | Idenix Pharmaceuticals, Inc. | Seven-membered ring nucleosides |
| WO2007025090A2 (en) | 2005-08-25 | 2007-03-01 | Kalypsys, Inc. | Heterobicyclic and - tricyclic inhibitors of mapk/erk kinase |
| JP2009507032A (ja) | 2005-09-02 | 2009-02-19 | アボット・ラボラトリーズ | 新規なイミダゾ系複素環 |
| US20070078136A1 (en) | 2005-09-22 | 2007-04-05 | Bristol-Myers Squibb Company | Fused heterocyclic compounds useful as kinase modulators |
| US7723336B2 (en) | 2005-09-22 | 2010-05-25 | Bristol-Myers Squibb Company | Fused heterocyclic compounds useful as kinase modulators |
| EP1934214B1 (en) | 2005-09-27 | 2010-04-07 | F.Hoffmann-La Roche Ag | Oxadiazolyl pyrazolo-pyrimidines as mglur2 antagonists |
| BRPI0616722A2 (pt) | 2005-09-30 | 2012-12-25 | Astrazeneca Ab | composto ou um sal farmaceuticamente aceitÁvel ou um Éster hidrolisÁvel in vivo do mesmo, processo para preparar o mesmo, composiÇço farmacÊutica, uso de um composto ou um sal farmaceuticamente aceitÁvel ou um Éster hidrolisÁvel in vivo do mesmo, e, mÉtodos para produzir um efeito anti-proliferaÇço celular e um efeito inibidor cdk2, para tratar cÂncer, e para tratar doenÇas |
| JO2769B1 (en) | 2005-10-26 | 2014-03-15 | جانسين فارماسوتيكا ان. في | Rapid decomposition of physiologically antagonistic agents of the 2-dopamine receptor |
| WO2007058942A2 (en) | 2005-11-10 | 2007-05-24 | Schering Corporation | Imidazopyrazines as protein kinase inhibitors |
| EP1945216A1 (en) | 2005-11-10 | 2008-07-23 | Schering Corporation | Methods for inhibiting protein kinases |
| WO2007078815A2 (en) | 2005-12-16 | 2007-07-12 | Cytokinetics, Inc. | Certain chemical entities, compositions, and methods |
| EP1989205B1 (en) | 2006-01-23 | 2012-06-13 | Vertex Pharmceuticals Incorporated | Thiophene-carboxamides useful as inhibitors of protein kinases |
| EP1984375A2 (en) | 2006-01-25 | 2008-10-29 | Smithkline Beecham Corporation | Chemical compounds |
| JP2009528388A (ja) | 2006-03-02 | 2009-08-06 | スミスクライン・ビーチャム・コーポレイション | Ｐｉ３キナーゼ阻害物質として用いられるチアゾロン |
| US20090175852A1 (en) | 2006-06-06 | 2009-07-09 | Schering Corporation | Imidazopyrazines as protein kinase inhibitors |
| MX2008015747A (es) | 2006-06-06 | 2008-12-19 | Schering Corp | Imidazopirazinas como inhibidores de la proteina quinasa. |
| ITVA20060041A1 (it) | 2006-07-05 | 2008-01-06 | Dialectica Srl | Uso di composti derivati amminotiazolici, di loro composizioni farmaceutiche, nel trattamento di malattie caratterizzate dalla anormale repressione della trascrizione genica, particolarmente il morbo di huntington |
| WO2008011557A2 (en) | 2006-07-20 | 2008-01-24 | Borchardt Allen J | Heteroaryl inhibitors of rho kinase |
| JP2009544723A (ja) | 2006-07-24 | 2009-12-17 | スミスクライン・ビーチャム・コーポレイション | Ｐｉ３キナーゼ阻害剤としてのチオゾリジンジオン誘導体 |
| US7563797B2 (en) | 2006-08-28 | 2009-07-21 | Forest Laboratories Holding Limited | Substituted imidazo(1,2-A)pyrimidines and imidazo(1,2-A) pyridines as cannabinoid receptor ligands |
| WO2008030795A2 (en) | 2006-09-05 | 2008-03-13 | Boards Of Regents, The University Of Texas System | Compositions and methods for inhibition of tyrosine kinases |
| JP5600004B2 (ja) | 2006-09-05 | 2014-10-01 | エモリー ユニバーシティー | 感染の予防または治療のためのチロシンキナーゼ阻害剤 |
| CA2663091A1 (en) | 2006-09-07 | 2008-03-13 | Biogen Idec Ma Inc. | Modulators of interleukin-1 receptor-associated kinase |
| CN101553224A (zh) | 2006-10-06 | 2009-10-07 | 艾博特公司 | 新型咪唑并噻唑和咪唑并唑 |
| WO2008053285A1 (en) | 2006-10-30 | 2008-05-08 | Draximage Limited | Methods for preparing 2-methoxyisobutylisonitrile and tetrakis(2-methoxyisobutylisonitrile)copper(i) tetrafluoroborate |
| WO2008057402A2 (en) | 2006-11-02 | 2008-05-15 | Cytovia, Inc. | N-aryl-isoxazolopyrimidin-4-amines and related compounds as activators of caspases and inducers of apoptosis and the use thereof |
| AR063581A1 (es) | 2006-11-08 | 2009-02-04 | Schering Corp | Imidazopirazinas como inhibidores de proteina quinasa |
| US20080221092A1 (en) | 2006-11-20 | 2008-09-11 | Harald Bluhm | Heterobicyclic metalloprotease inhibitors |
| US7622584B2 (en) | 2006-11-24 | 2009-11-24 | Samsung Mobile Display Co., Ltd. | Imidazopyridine-based compound and organic light emitting diode including organic layer comprising the imidazopyridine-based compound |
| RU2469034C2 (ru) | 2006-12-04 | 2012-12-10 | Астразенека Аб | Химические соединения |
| US7977336B2 (en) | 2006-12-28 | 2011-07-12 | Banyu Pharmaceutical Co. Ltd | Aminopyrimidine derivatives as PLK1 inhibitors |
| AU2008205642B2 (en) | 2007-01-12 | 2013-06-06 | Msd K.K. | Spirochromanon derivatives |
| US20080242862A1 (en) | 2007-03-27 | 2008-10-02 | Calderwood David J | Novel imidazo based heterocycles |
| JP2010522765A (ja) | 2007-03-28 | 2010-07-08 | アレイ バイオファーマ、インコーポレイテッド | 受容体チロシンキナーゼとしてのイミダゾ［１，２−ａ］ピリジン化合物 |
| HRP20130660T1 (en) | 2007-04-03 | 2013-08-31 | Array Biopharma, Inc. | Imidazo[1,2-a]pyridine compounds as receptor tyrosine kinase inhibitors |
| EP2155744A1 (en) | 2007-04-10 | 2010-02-24 | Lundbeck, H., A/S | Heteroaryl amide analogues as p2x7 antagonists |
| WO2008133192A1 (ja) | 2007-04-19 | 2008-11-06 | Takeda Pharmaceutical Company Limited | 縮合イミダゾール化合物およびその用途 |
| WO2008134553A1 (en) | 2007-04-26 | 2008-11-06 | Xenon Pharmaceuticals Inc. | Methods of using bicyclic compounds in treating sodium channel-mediated diseases |
| US20100305113A1 (en) | 2007-05-09 | 2010-12-02 | Hans-Georg Capraro | Substituted Imidazopyridazines as Lipid Kinase Inhibitors |
| US8242085B2 (en) | 2007-05-10 | 2012-08-14 | Biocryst Pharmaceuticals, Inc. | Tetrahydrofuro [3,4-D] dioxolane compounds for use in the treatment of viral infections and cancer |
| BRPI0811898A2 (pt) | 2007-06-01 | 2019-09-24 | Glaxosmithkline Llc | composto, composição farmacêutica, métodos para tratar um neoplasma suscetível e um câncer em um mamífero, processo para preparar um composto, e, uso de um composto. |
| CA2690557A1 (en) | 2007-06-14 | 2008-12-24 | Schering Corporation | Imidazopyrazines as protein kinase inhibitors |
| KR101030007B1 (ko) | 2007-06-15 | 2011-04-20 | 삼성모바일디스플레이주식회사 | 헤테로방향환 함유 화합물, 이의 제조 방법 및 이를 이용한유기 발광 소자 |
| EP2170882A1 (en) | 2007-06-26 | 2010-04-07 | Gilead Colorado, Inc. | Imidazopyridinyl thiazolyl histone deacetylase inhibitors |
| FR2918061B1 (fr) | 2007-06-28 | 2010-10-22 | Sanofi Aventis | Derives de 6-cycloamino-3-(pyridin-4-yl)imidazo°1,2-b!- pyridazine,leur preparation et leur application en therapeutique. |
| US8188083B2 (en) | 2007-06-28 | 2012-05-29 | Abbott Laboratories | Triazolopyridazines |
| FR2918986B1 (fr) | 2007-07-19 | 2009-09-04 | Sanofi Aventis Sa | Derives de 6-cycloamino-3-(pyridazin-4-yl)imidazo[1,2-b]- pyridazine, leur preparation et leur application en therapeutique |
| CN101790515A (zh) | 2007-07-27 | 2010-07-28 | 埃科特莱茵药品有限公司 | 反式-3-氮杂-双环[3.1.0]己烷衍生物 |
| AU2008282885A1 (en) | 2007-07-31 | 2009-02-05 | Schering Corporation | Anti-mitotic agent and aurora kinase inhibitor combination as anti-cancer treatment |
| CA2695989A1 (en) | 2007-08-10 | 2009-02-19 | Glaxosmithkline Llc | Certain nitrogen containing bicyclic chemical entities for treating viral infections |
| PA8793301A1 (es) | 2007-08-14 | 2009-04-23 | Bayer Schering Pharma Ag | Imidazoles bicíclicos fusionados |
| EP2190844B3 (en) | 2007-08-15 | 2013-07-17 | Arena Pharmaceuticals, Inc. | Imidazo[1,2-a]pyridine derivatives as modulators of the 5-ht2a serotonin receptor useful for the treatment of disorders related thereto |
| GB0716292D0 (en) | 2007-08-21 | 2007-09-26 | Biofocus Dpi Ltd | Imidazopyrazine compounds |
| US20110046127A1 (en) | 2007-11-08 | 2011-02-24 | Paolo Pevarello | Imidazopyridazines for Use as Protein Kinase Inhibitors |
| WO2009061856A1 (en) | 2007-11-09 | 2009-05-14 | The Salk Instituite For Biological Studies | Non-nucleoside reverse transcriptase inhibitors |
| US7875618B2 (en) * | 2007-11-30 | 2011-01-25 | Wyeth | Substituted imidazo[1,5-a]quinoxalines useful as inhibitors of phosphodiesterase 10 for the treatment of neurological and other disorders |
| EP2229390B1 (en) | 2007-12-14 | 2014-04-09 | F. Hoffmann-La Roche AG | Novel imidazoý1,2-a¨pyridine and imidazoý1,2-b¨pyridazine derivatives |
| US20100331333A1 (en) | 2007-12-21 | 2010-12-30 | Wyeth Llc | Imidazo [1,2-B] Pyridazine Compounds |
| JP5355421B2 (ja) | 2007-12-21 | 2013-11-27 | 出光興産株式会社 | 有機エレクトロルミネッセンス素子 |
| BRPI0822237A2 (pt) | 2007-12-21 | 2015-06-30 | Wyeth Llc | Compostos de imidazo [1,2-a] piridina |
| FR2926556B1 (fr) | 2008-01-22 | 2010-02-19 | Sanofi Aventis | Derives de carboxamides n-azabicycliques, leur preparation et leur application en therapeutique |
| CA2710929A1 (en) | 2008-01-28 | 2009-08-06 | Schering Corporation | Imidazopyrazines as protein kinase inhibitors |
| US8329697B2 (en) | 2008-02-26 | 2012-12-11 | Merck Sharp & Dohme Corp. | Imidizo[1,2-A]pyrazines useful as AHCY hydrolase inhibitors |
| CA2716856C (en) | 2008-03-20 | 2013-02-19 | Amgen Inc. | Aurora kinase modulators and method of use |
| DE102008017853A1 (de) | 2008-04-09 | 2009-10-15 | Merck Patent Gmbh | Thienopyrimidine |
| TW201000107A (en) | 2008-04-09 | 2010-01-01 | Infinity Pharmaceuticals Inc | Inhibitors of fatty acid amide hydrolase |
| HUE038946T2 (hu) | 2008-04-23 | 2018-12-28 | Gilead Sciences Inc | 1'-szubsztituált carba-nukleozid analógok antivirális kezelésre |
| WO2010036407A2 (en) | 2008-05-15 | 2010-04-01 | Biocryst Pharmaceuticals, Inc. | Antiviral nucleoside analogs |
| EP2300470A2 (en) | 2008-05-19 | 2011-03-30 | Sepracor Inc. | Imidazo[1,2-a]pyridine compounds as gaba-a receptor modulators |
| US20110077248A1 (en) | 2008-05-29 | 2011-03-31 | Sirtris Pharmaceuticals, Inc. | Imidazopyridine and related analogs as sirtuin modulators |
| AR072008A1 (es) | 2008-06-13 | 2010-07-28 | Merck & Co Inc | Compuestos heterobiciclicos como agentes de inhibicion de quinasa p38 |
| EP2306836B1 (en) | 2008-07-01 | 2016-09-07 | PTC Therapeutics, Inc. | Bmi-1 protein expression modulators |
| CA2729965A1 (en) | 2008-07-14 | 2010-01-21 | Gilead Sciences, Inc. | Fused heterocyclyc inhibitor compounds |
| WO2010011837A1 (en) | 2008-07-24 | 2010-01-28 | Bristol-Myers Squibb Company | Fused heterocyclic compounds useful as kinase modulators |
| CA2731368C (en) | 2008-08-06 | 2013-05-14 | Pfizer Inc. | 6 substituted 2-heterocyclylamino pyrazine compounds as chk-1 inhibitors |
| FR2934994B1 (fr) | 2008-08-12 | 2010-09-17 | Sanofi Aventis | Derives de 2-alkyl-6cycloamino-3-(pyridin-4-yl)imidaz°1,2-b! pyridazine, leur preparation et leur application en therapeutique |
| US8198449B2 (en) | 2008-09-11 | 2012-06-12 | Bristol-Myers Squibb Company | Compounds for the treatment of hepatitis C |
| WO2010033906A2 (en) | 2008-09-19 | 2010-03-25 | President And Fellows Of Harvard College | Efficient induction of pluripotent stem cells using small molecule compounds |
| WO2010048149A2 (en) | 2008-10-20 | 2010-04-29 | Kalypsys, Inc. | Heterocyclic modulators of gpr119 for treatment of disease |
| JP5416944B2 (ja) | 2008-10-23 | 2014-02-12 | ユー・ディー・シー アイルランド リミテッド | 有機電界発光素子 |
| WO2010054253A1 (en) | 2008-11-07 | 2010-05-14 | Biotie Therapies Gmbh | Triazine derivatives as inhibitors of phosphodiesterases |
| WO2010059838A2 (en) | 2008-11-20 | 2010-05-27 | Decode Genetics Ehf | Pde4 inhibitors selective for the long form of pde4 for treating inflammation and avoiding side effects |
| WO2010059836A1 (en) | 2008-11-20 | 2010-05-27 | Decode Genetics Ehf | Substituted aza-bridged bicyclics for cardiovascular and cns disease |
| GB0822981D0 (en) | 2008-12-17 | 2009-01-21 | Summit Corp Plc | Compounds for treatment of duchenne muscular dystrophy |
| WO2010077992A1 (en) * | 2008-12-17 | 2010-07-08 | Amgen Inc. | Aminopyridine and carboxypyridine compounds as phosphodiesterase 10 inhibitors |
| JP5210187B2 (ja) | 2009-01-22 | 2013-06-12 | ユー・ディー・シー アイルランド リミテッド | 有機電界発光素子 |
| EP2210891A1 (en) | 2009-01-26 | 2010-07-28 | Domain Therapeutics | New adenosine receptor ligands and uses thereof |
| WO2010088518A2 (en) | 2009-01-31 | 2010-08-05 | Kalypsys, Inc. | Heterocyclic modulators of gpr119 for treatment of disease |
| WO2010097367A1 (en) * | 2009-02-24 | 2010-09-02 | Janssen Pharmaceutica Nv | Radiolabelled pde10 ligands |
| US8367222B2 (en) | 2009-02-27 | 2013-02-05 | Idemitsu Kosan Co., Ltd. | Organic electroluminescent device |
| CN102341399A (zh) | 2009-03-05 | 2012-02-01 | 安斯泰来制药株式会社 | 喹喔啉化合物 |
| US8729074B2 (en) | 2009-03-20 | 2014-05-20 | Amgen Inc. | Inhibitors of PI3 kinase |
| JP5528427B2 (ja) | 2009-03-24 | 2014-06-25 | 出光興産株式会社 | 有機エレクトロルミネッセンス素子 |
| MX2011010915A (es) | 2009-04-16 | 2012-01-27 | Ct Nac Investigaciones Oncologicas Cnio | Imidazopirazinas para usarse como inhibidores decinasa. |
| TW201111383A (en) | 2009-05-29 | 2011-04-01 | Wyeth Llc | Substituted imidazo[1,5-a]quinoxalines as inhibitors of phosphodiesterase 10 |
| TW201107329A (en) | 2009-07-30 | 2011-03-01 | Oncotherapy Science Inc | Fused imidazole derivative having ttk inhibitory action |
| JP5709752B2 (ja) | 2009-08-19 | 2015-04-30 | 出光興産株式会社 | 芳香族アミン誘導体及びそれを用いた有機エレクトロルミネッセンス素子 |
| NZ599597A (en) | 2009-10-30 | 2013-05-31 | Janssen Pharmaceutica Nv | IMIDAZO[1,2-b]PYRIDAZINE DERIVATIVES AND THEIR USE AS PDE10 INHIBITORS |
| KR101580074B1 (ko) | 2009-11-16 | 2015-12-23 | 이데미쓰 고산 가부시키가이샤 | 방향족 아민 유도체 및 그것을 이용한 유기 전기발광 소자 |
| CA2787714C (en) | 2010-01-22 | 2019-04-09 | Joaquin Pastor Fernandez | Inhibitors of pi3 kinase |
| AR080754A1 (es) | 2010-03-09 | 2012-05-09 | Janssen Pharmaceutica Nv | Derivados de imidazo (1,2-a) pirazina y su uso como inhibidores de pde10 |
| US9540379B2 (en) | 2011-01-31 | 2017-01-10 | Boehringer Ingelheim International Gmbh | (1,2,4)triazolo[4,3-A]quinoxaline derivatives as inhibitors of phosphodiesterases |
| CA2833304A1 (en) | 2011-04-28 | 2012-11-01 | Janssen Pharmaceutica Nv | Salt of an inhibitor of phoshodiesterase 10 enzyme |
| ES2575092T3 (es) | 2011-06-27 | 2016-06-24 | Janssen Pharmaceutica, N.V. | Derivados de 1-aril-4-metil-[1,2,4]triazolo[4,3-a]quinoxalina |
| EP2763989A1 (en) | 2011-09-09 | 2014-08-13 | H. Lundbeck A/S | Pyridine compounds and uses thereof |
| WO2013034755A1 (en) | 2011-09-09 | 2013-03-14 | H. Lundbeck A/S | Triazolopyrazine derivatives and their use for treating neurological and psychiatric disorders |
| KR102171706B1 (ko) | 2012-07-09 | 2020-10-30 | 얀센 파마슈티카 엔.브이. | 포스포디에스테라아제 10 효소의 억제제 |
-
2012
- 2012-06-26 ES ES12729637.4T patent/ES2575092T3/es active Active
- 2012-06-26 MX MX2013015201A patent/MX344600B/es active IP Right Grant
- 2012-06-26 AU AU2012277912A patent/AU2012277912B2/en not_active Ceased
- 2012-06-26 BR BR112013033375-8A patent/BR112013033375B1/pt not_active IP Right Cessation
- 2012-06-26 US US14/128,835 patent/US10604523B2/en not_active Expired - Fee Related
- 2012-06-26 EA EA201490165A patent/EA027418B1/ru not_active IP Right Cessation
- 2012-06-26 WO PCT/EP2012/062381 patent/WO2013000924A1/en not_active Ceased
- 2012-06-26 CA CA2838645A patent/CA2838645C/en active Active
- 2012-06-26 CN CN201280031255.3A patent/CN103619846B/zh not_active Expired - Fee Related
- 2012-06-26 EP EP12729637.4A patent/EP2723744B1/en active Active
- 2012-06-26 JP JP2014517667A patent/JP6115962B2/ja not_active Expired - Fee Related
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2014518234A5 (enExample) | ||
| JP4754068B2 (ja) | δ−オピオイドレセプターに結合する４−［アリール（ピペリジン−４−イル）］アミノベンズアミド類 | |
| EP2370437B1 (en) | Bicyclic pyrazole and isoxazole derivatives as antitumor and antineurodegenerative agents | |
| JP4284182B2 (ja) | アデノシンＡ２ａレセプターアンタゴニスト | |
| CA2463598C (en) | Imidazo (4,3-e)-1,2,4-triazolo(1,5-c) pyrimidines as adenosine a2a receptor antagonists | |
| US7183415B2 (en) | Quinoline compound | |
| AU2014284616B2 (en) | Novel bicyclic bromodomain inhibitors | |
| RU2666730C2 (ru) | Диазольные лактамы | |
| ES2442926T3 (es) | Derivados de ciclopropilamida `978 | |
| CN101686952A (zh) | 新型钙离子通道调节剂 | |
| KR101165504B1 (ko) | 벤조이미다졸 화합물 및 그의 의약 용도 | |
| US10294227B2 (en) | Compounds | |
| JP2018500342A (ja) | トリアゾロピリミジン化合物およびその使用 | |
| RU2016139690A (ru) | Новые соединения в качестве ингибиторов гистондеацетилазы 6 и содержащие их фармацевтические композиции | |
| EA015034B1 (ru) | 2-анилин-4-арилзамещенные тиазольные производные | |
| JP2016520118A (ja) | Ｂｅｔ阻害剤としてのピラゾロ−ピロリジン−４−オン誘導体および疾患の処置におけるその使用 | |
| JP2006514110A5 (enExample) | ||
| JP2013144719A5 (enExample) | ||
| EA037481B1 (ru) | Производные 3-((гетеро-)арил)алкил-8-амино-2-оксо-1,3-диазаспиро[4.5]декана | |
| JP6082457B2 (ja) | Ｇｐｒ１７受容体調節因子 | |
| JP2008501758A (ja) | ピロロピリジン誘導体 | |
| CA3236339A1 (en) | Indolizine compounds for the treatment of mental disorders or mental enhancement | |
| SK83098A3 (en) | 1-(1,2-disubstituted piperidinyl)-4-(fused imidazole)-piperidine derivatives | |
| Sippy et al. | Preparation and characterization of N-(3-pyridinyl) spirocyclic diamines as ligands for nicotinic acetylcholine receptors | |
| JP4740152B2 (ja) | 末梢性５−ｈｔ受容体の修飾因子 |